

1 **The Healthy Brain Initiative (HBI): A prospective cohort study protocol**

2 Lilah M. Besser<sup>a</sup>, Stephanie Chrisphonte<sup>a</sup>, Michael J. Kleiman<sup>a</sup>, Deirdre O'Shea<sup>a</sup>, Amie  
3 Rosenfeld, DPT<sup>a</sup>, Magdalena Tolea<sup>a</sup>, James E. Galvin<sup>a</sup>

4 <sup>a</sup> Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller  
5 School of Medicine, 7700 Camino Real Suite 200, Boca Raton, FL 33433

6

7 **Abstract**

8 **Background:** The Health Brain Initiative (HBI), established by University of Miami's  
9 Comprehensive Center for Brain Health (CCBH), follows racially/ethnically diverse older adults  
10 without dementia living in South Florida. With dementia prevention and brain health promotion  
11 as an overarching goal, HBI will advance scientific knowledge by developing novel assessments  
12 and non-invasive biomarkers of Alzheimer's disease and related dementias (ADRD), examining  
13 additive effects of sociodemographic, lifestyle, neurological and biobehavioral measures, and  
14 employing innovative, methodologically advanced modeling methods to characterize ADRD risk  
15 and resilience factors and transition of brain aging.

16 **Methods:** HBI is a longitudinal, observational cohort study that will follow 500 deeply-  
17 phenotyped participants annually to collect, analyze, and store clinical, cognitive, behavioral,  
18 functional, genetic, and neuroimaging data and biospecimens. Participants are ≥50 years old;  
19 have no, subjective, or mild cognitive impairment; have a study partner; and are eligible to  
20 undergo magnetic resonance imaging (MRI). Recruitment is community-based including  
21 advertisements, word-of-mouth, community events, and physician referrals. At baseline,  
22 following informed consent, participants complete detailed web-based surveys (e.g.,  
23 demographics, health history, risk and resilience factors), followed by two half-day visits which  
24 include neurological exams, cognitive and functional assessments, an overnight sleep study,  
25 and biospecimen collection. Structural and functional MRI is completed by all participants and a  
26 subset also consent to amyloid PET imaging. Annual follow-up visits repeat the same data and

27 biospecimen collection as baseline, except that MRIs are conducted every other year after  
28 baseline.

29 **Ethics and expected impact:** HBI has been approved by the University of Miami Miller School  
30 of Medicine Institutional Review Board. Participants provide informed consent at baseline and  
31 are re-consented as needed with protocol changes. Data collected by HBI will lead to  
32 breakthroughs in developing new diagnostics and therapeutics, create comprehensive  
33 diagnostic evaluations, and provide the evidence base for precision medicine approaches to  
34 dementia prevention with individualized treatment plans.

## 35 INTRODUCTION

36 Alzheimer's disease and related dementias (ADRD) affect approximately 55 million individuals  
37 worldwide, and the prevalence is projected to rise with the expected surge in the population of  
38 older adults over the next few decades (1). ADRD are neurodegenerative diseases that result in  
39 cognitive and functional decline, with initial symptoms varying based on etiology. For example,  
40 Alzheimer's disease (AD), which involves the accumulation of amyloid plaques and tau tangles  
41 throughout the brain, typically begins with episodic memory problems experienced during older  
42 age (e.g.  $\geq 65$  years) (2). In contrast, Lewy body dementia (LBD), which is associated with the  
43 accumulation of alpha-synuclein protein or Lewy bodies in the brain, usually presents as having  
44 motor symptoms, cognitive fluctuations, rapid eye movement (REM) sleep behavior disorder,  
45 and/or visual hallucinations starting at age 50 or older (3). Some recent advances have been  
46 made in clinical trials, such as monoclonal antibody treatments (e.g., aducanumab, lecanumab,  
47 donanemab), which have been shown to remove amyloid plaques and slow cognitive decline  
48 among individuals with early AD (4). These monoclonal antibody treatments have been  
49 associated with amyloid-related imaging abnormalities and therefore require careful monitoring  
50 with serial Magnetic Resonance Imaging (MRI) (5) that is costly, time-consuming, and  
51 burdensome. However, no treatments are presently available to prevent incipient ADRD. Thus,  
52 while much research effort remains directed at drug development focused on removing ADRD  
53 pathology to slow or halt cognitive decline amongst symptomatic individuals, there is still a great  
54 need for studies to identify at-risk individuals and develop primary and secondary prevention  
55 strategies.

56  
57 Older age, familial dominant genetic mutations (e.g., APP, PSEN1, PSEN2 for AD), and genetic  
58 risk factors (e.g.,  $\geq 1$  apolipoprotein e4 allele) contribute significantly to an individual's  
59 vulnerability toward developing ADRD (6). Beyond these non-modifiable risk factors, 12  
60 modifiable risk factors were identified by the Lancet Commission in 2020 as significant

61 contributors to dementia risk based on a review of the extant literature (7). These risk factors,  
62 which were estimated to account for approximately 40% of dementias worldwide, include less  
63 education, smoking, obesity, hearing impairment, depression, physical inactivity, hypertension,  
64 diabetes, low social contact, traumatic brain injury (TBI), alcohol consumption, and air pollution  
65 exposure. The estimates of population attributable fraction (PAF) from the Lancet commission  
66 have been modified over time (from 2017 (8) to 2020 (7)) to add TBI, air pollution, and alcohol  
67 use), and will likely be modified again as evidence accumulates for additional risk factors that  
68 have not been adequately studied to date. In addition, the PAF estimates were based on a  
69 sample in the United Kingdom, which might have different risk factors that regions with differing  
70 diversity by factors such as racial/ethnic group. Altogether, the 12 identified risk factors  
71 represent an initial list of important dementia risk factors that will likely be expanded based on  
72 evidence from new studies and more diverse cohorts.

73

74 Recently, clinical and epidemiological studies have shifted to not only focus on risk factors for  
75 developing dementia, but also on the unique factors that impart resistance against the  
76 development of ADRD neuropathology or resilience against cognitive decline in the face of  
77 underlying neuropathology (9). This shift in orientation parallels an increased research interest  
78 in brain health, which is the “preservation of optimal brain integrity and mental and cognitive  
79 function at a given age in the absence of overt brain diseases that affect normal brain function”  
80 (10). Pathology associated with ADRD can begin decades before initial symptom presentation,  
81 during the midlife period (11). Use of biomarkers such as those ascertained from cerebrospinal  
82 fluid and blood (e.g., amyloid beta, p-Tau) is particularly important to help identify protective  
83 factors associated with lowering ADRD risk when symptoms have not yet manifested but  
84 pathology may be present. While growing, research is limited on risk and protective factors in  
85 relation to ADRD biomarkers with an eye toward cognitive reserve and resilience. In addition,  
86 research needs to expand to investigate neurobehavioral biomarkers strongly predictive of

87 ADRD but that are less invasive than the established biomarkers that require magnetic  
88 resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF), or  
89 blood or skin biopsy collection (12), and that could be applied in clinical practice.

90

91 The NIA-AA research ATN framework emphasizes the incorporation of biomarker measures of  
92 amyloid, tau, and neurodegeneration/neuronal injury, providing an opportunity to classify  
93 individuals across the AD spectrum (13). For instance, abnormal amyloid levels have been  
94 consistently shown to predict subsequent cognitive decline as well as progression to mild  
95 cognitive impairment and dementia (14-17). Risk of future decline among amyloid+ normal  
96 controls is particularly high in those that also have abnormal tau (14, 18) or neurodegeneration  
97 (19-21). Combining information across ATN dimensions allows identification of clinically normal  
98 individuals who are in the earliest stages of the AD spectrum (“preclinical AD”). In addition, ATN  
99 dimensions can be applied in differential diagnosis (13, 21-23), assessing target engagement  
100 during clinical trials (24), and determine presence of other pathologies such as Lewy bodies (13,  
101 25). Overall, the ATN framework provides a new perspective for studies of risk for and resilience  
102 against ADRD. Recently, revisions have been proposed for the ATN framework to incorporate  
103 other markers of neuronal injury, neurodegeneration, and coexisting pathologies (e.g., vascular  
104 lesions, Lewy bodies).

105

106 The gaps in the literature on ADRD risk and protective factors, cognitive reserve, and resilience  
107 are particularly apparent for minoritized and disadvantaged populations (e.g., racial/ethnic  
108 minoritized and lower socioeconomic status (SES) groups) (26). It is critical for future work on  
109 brain health promotion and ADRD prevention to focus on protective factors for these  
110 populations, who also appear to be at higher risk of developing ADRD (6). For instance, Black  
111 and Hispanic individuals are 1.5 to 2 times more likely to develop ADRD than White individuals,  
112 and risk is highest amongst those with a combination of low education and low lifetime

113 occupational attainment (27). Factors that can be targeted via intervention to reduce ADRD risk  
114 may differ between socially disadvantaged and advantaged individuals, and new cohorts are  
115 needed with diverse populations including understudied immigrant populations.

116

117 Studies on unique factors promoting cognitive reserve and resilience (beyond known risk  
118 factors) that can be targeted via intervention to prevent ADRD remain limited. The Health Brain  
119 Initiative (HBI) cohort was established by University of Miami's Comprehensive Center for Brain  
120 Health (CCBH) to fill this gap and advance beyond the studies of healthy brain aging and ADRD  
121 research to date. HBI will follow a racially/ethnically diverse cohort of  $\geq 50$ -year-olds with normal  
122 cognition, subjective cognitive complaints, mild cognitive impairment or very mild dementia from  
123 the South Florida region. With ADRD prevention and brain health promotion as an overarching  
124 goal, HBI will advance scientific knowledge on established and novel ADRD biomarkers,  
125 examine additive effects of multiple factors (e.g., sociodemographics and lifestyle) on risk,  
126 reserve, and resilience, and employ innovative and methodologically advanced methods to  
127 characterize risk/resilience factors and disease progression.

128

## 129 **MATERIALS AND METHODS**

130

### 131 ***Study aims, design, and setting***

132

133 The HBI is a longitudinal, observational cohort study that will prospectively collect, analyze,  
134 maintain, and store clinical, cognitive, behavioral, functional and neuroimaging data and  
135 biospecimens from research participants, to allow a characterization of transitions in cognitive  
136 status, studying risk and protective factors for cognitive and functional decline, and creation of a  
137 repository of data for future research questions. The cohort will have representative sampling by  
138 sex, race and ethnicity for normal cognition (NIA-AA Stage 1), subjective memory complaints

139 (Stage 2), MCI (Stage 3), or mild ADRD (Stage 4) according to the ATN framework (13). HBI's  
140 specific aims are to:

- 141 1) Characterize novel approaches for detection of healthy brain aging and ADRD and  
142 examine their relationship to ADRD biomarkers and ADRD-related outcomes (Aim  
143 1);
- 144 2) Examine potential sociodemographic, biological, genetic, health and lifestyle additive  
145 effects on the presence and accumulations of ADRD pathology detected via  
146 biomarkers that may confer risk and resilience to cognitive decline (Aim 2);
- 147 3) Determine whether potentially modifiable risk factors across the life course buffer the  
148 impact of brain pathology on cognitive decline and thus can serve as intervention  
149 targets (Aim 3);
- 150 4) Use machine learning and other advanced analytic techniques to explore trajectories  
151 of disease progression by baseline health, lifestyle, and other risk factors (Aim 4);  
152 and,
- 153 5) Conduct study aims with a racially/ethnically and socioeconomically diverse cohort  
154 that will allow for examination of disparities in biomarkers, ADRD outcomes, and  
155 risk/protective factors (Aim 5).

156  
157 HBI will recruit a longitudinal cohort of 500 participants living in the racially/ethnically diverse  
158 South Florida region, primarily Palm Beach and Broward counties. Multiple grant-funded studies  
159 will use the standardized HBI protocol for data collection and thus contribute to the target  
160 recruitment goals for HBI (e.g., NIH R01AG071514, R01AG071514S1, R01NS101483,  
161 R01NS101483S1, RF1AG075901, and R56AG074889).

162  
163 Recruitment will occur through a variety of sources, including advertisements, word-of-mouth,  
164 community lectures, health fairs, community events, educational conferences, physician

165 referrals, and working with community partners. HBI has an IRB-approved cross-sectional  
166 survey of risk and resilience factors that can be used to identify eligible individuals. Individuals  
167 who call the center will be provided with IRB-approved literature regarding the study objectives  
168 and inclusion/exclusion criteria. A full-time bilingual recruitment coordinator will work in  
169 conjunction with the research staff to organize and conduct recruitment activities.

170

171 Annual visits will be conducted at University of Miami's Comprehensive Center for Brain Health  
172 (CCBH) in Boca Raton, Florida. The visits will involve both the participant and their study  
173 partner, who is typically a spouse or adult child who provides independent, collateral information  
174 on the participant. Our prior research has demonstrated the importance of the caregiver-patient  
175 dyad to longitudinal outcomes (28-31).

176

#### 177 **Inclusion and exclusion criteria**

178

179 The target sample of 500 individuals to be followed longitudinally will include those who:

- 180 • Are  $\geq 50$  years old,
- 181 • Have no cognitive impairment, subjective cognitive impairment (SCI), mild cognitive  
182 impairment (MCI), or any cause of dementia or neurodegenerative disease at the mild  
183 stage (Clinical Dementia Rating (CDR®)  $\leq 1$ ),
- 184 • Have a study partner; and,
- 185 • Are medically eligible to undergo MRI.

186

187 Individuals will be excluded if they:

- 188 • Do not consent for data/specimen storage,

- 189       • Have already been diagnosed with moderate or severe ADRD (Clinical Dementia  
190       Rating $\geq$ 2 (32)),
- 191       • Cannot contribute clinical, cognitive, behavioral, or functional data; or,
- 192       • Have significant medical illness that could affect participation in imaging or obfuscate  
193       relevant cognitive outcomes (e.g., metastatic cancer, primary Axis I disorder such as  
194       schizophrenia, Axis II personality disorder, unstable diabetes or hypertension, or  
195       substance abuse within the past 5 years).

196

## 197 **Procedures**

198

199 *Baseline visit.* Participants and their study partners will be consented at the baseline visit, and  
200 then re-consented at annual follow-ups if needed. Following informed consent, the participants  
201 will complete a battery of questionnaires collecting information such as demographics, medical  
202 history to identify possible risk factors for memory problems (e.g., high blood pressure, strokes,  
203 heart disease, diabetes, other potentially relevant comorbidities), lifestyle activities, and  
204 resilience and vulnerability factors (Tables 1 and 2).

205

206 Once the battery of questionnaires is completed and reviewed by the study team for  
207 completeness, the baseline visit is scheduled. The visit will include blood sample collection,  
208 detailed neuropsychological, physical function, neurological, and psychosocial assessments,  
209 and participants receive an actigraphy and peripheral arterial tone device (i.e., Watch PAT) for  
210 overnight sleep monitoring and have their MRI scheduled (Table 3). The full baseline visit is  
211 expected to take two half days to complete. Participants recruited for certain grant-funded  
212 projects that include the HBI assessment also will be scheduled to obtain an amyloid PET using  
213 <sup>18</sup>F-Fluorbetaben.

214

215 The research visit concludes with a feedback session during which a research clinician (e.g.,  
216 physician, nurse practitioner) meets with the participant and study partner (optional) to go over  
217 results of the neurological examination, physical performance, neurobehavioral status, and  
218 cognitive evaluation. This meeting also will provide health recommendations, education,  
219 resources and referrals based on the findings. This feedback can be shared with family and/or a  
220 doctor at the participant's request. Once reviewed, participants will receive a summary of  
221 clinical laboratory results from a CLIA-approved lab. If any abnormalities are detected, the  
222 participant will be informed of results and encouraged to speak with their primary care provider  
223 for further evaluation. Results of genetic testing will not be shared with either the participant or  
224 their physicians as described in the consent form.

225

226 *In-person follow-up visits.* Annual follow-up visits will collect almost identical data as the  
227 baseline visit, and will include the neuropsychological battery, neurological evaluation, physical  
228 performance testing, and blood work, so that we can monitor annual changes in cognitive and  
229 physical status and biomarkers for ADRD. MRI are conducted every 2 years following the  
230 baseline visit, unless a clinically relevant event (e.g., conversion to dementia, stroke) occurs  
231 whereby they may be asked to undergo an MRI earlier.

232

233 *Telephone follow-ups.* At 3 and 6 months after the baseline visit and then at 6 months after the  
234 follow-up visits, each participant will be contacted by phone to update contact information,  
235 health history and medications, collect data on their cognition and everyday functioning, assess  
236 adherence with recommendations and referrals provided at the feedback session, and to  
237 support study retention.

238

239

240

241 **Physical and neurological examinations**

242

243 Each participant will provide information about their current and past health history (e.g.,  
244 medical, social, physical, environmental) through a 20-page self-administered questionnaire  
245 prior to the core visit. To confirm or rule out various types of neurodegenerative diseases  
246 (ADRD) a series of tests and examinations will be conducted during the study visit. The results  
247 of these procedures will be documented and used to relate objective and subjective findings,  
248 measures, and complaints for an accurate research diagnosis for each participant. Each study  
249 partner will complete an 11-page survey.

250

251 Advanced practice nurses and neurologists will complete a comprehensive physical and  
252 neurological examination of each participant (33, 34). This examination will include  
253 assessments of vital signs in a sitting and standing position, mental status, cranial nerve,  
254 reflexes, sensation, balance, coordination, and motor skills and includes the Unified Parkinson's  
255 Disease Rating Scale – Part III Motor Examination (35), modified Hoehn and Yahr staging (36),  
256 Lewy Body Composite Risk Score (37), modified Hachinski Ischemic Scale (38), and modified  
257 CAIDE scale (39).

258

259 *Overnight Sleep Study.* A disposable FDA-approved at home diagnostic test for sleep apnea will  
260 be given to each participant to wear overnight following the core visit procedures (40). This  
261 actigraphy and peripheral arterial tone device is placed on the wrist of the non-dominant hand, a  
262 probe is placed on the index finger of the non-dominant hand, and a sensor is placed on their  
263 chest just below the sternal notch. A smartphone is used to accompany the device using an  
264 app to start and end the test.

265

266 *Audiometry.* Headphones and a tablet computer with auditory testing software will be given to  
267 each participant (41). The hearing test will be conducted in a private space free of distractions  
268 for a duration of about ten minutes. Participants will be able to use the tablet independently after  
269 listening to the instructions provided on the tablet.

270

271 *Spirometry.* This test requires the participant to take a deep breath and then expel all the air in  
272 their lungs into a filtered mouthpiece that is connected to a spirometry device (42). This  
273 machine can measure peak expiratory flow (PEF), PEF%, FEV1 (forced expiratory volume),  
274 FEV1%, FVC (forced vital capacity), and FEV1/FVC.

275

276 *Ankle Brachial Index.* Cuffs are wrapped around the arm (brachial) and ankle (dorsalis pedis  
277 and posterior tibial) arterial sites bilaterally and a handheld doppler ultrasound device is used to  
278 measure systolic blood pressure while the participant is in a supine position at rest for 5 to 10  
279 minutes (43). This test will be used to assess peripheral artery disease.

280

281 *Color Blindness Test.* The Farnsworth D-15 Dichotomous Color Blindness Test will be  
282 administered digitally on a computer or laptop. Participants will be asked to arrange 15 color  
283 squares in order by choosing the most similar color and dragging the color squares into the  
284 upper boxes (44, 45). A pilot square is set as the first box.

285

## 286 **Cognitive assessments**

287 A comprehensive battery of both traditional (pencil and paper) and computerized tests will be  
288 employed to longitudinally assess aspects of cognition and mood. The battery will be conducted  
289 at baseline and then repeated at each subsequent annual follow-up. Specific tests and their  
290 associated details are provided below.

291

292 *The Clinical Dementia Rating scale* (CDR; 46) is a semi-structured interview, involving both the  
293 participant and a study partner, gauges cognitive and functional performance across six  
294 domains: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and  
295 Hobbies, and Personal Care. The CDR has good reliability and validity and detects subtle  
296 cognitive changes and everyday functioning. Each domain receives a score between 0 (no  
297 impairment) and 3 (severe impairment). An aggregate global score is then derived, indicating  
298 overall dementia severity (i.e., 0 =normal, 0.5 = MCI, 1,2,3= mild, moderate, or severe  
299 dementia, respectively). The sum of boxes score (CDR-SB) is calculated by summing domain  
300 scores with possible scores ranging from 0-18, with higher scores indicating greater impairment.

301

302 *The Global Deterioration Scale* (GDS; (47)) is a rating scale of cognitive status with a range of  
303 scores from 1-6. The GDS has advantages over the CDR by providing separate ratings for  
304 cognitively normal individuals with and without cognitive complaints. GDS 1 signifies cognitively  
305 normal individuals without any subjective complaints; GDS 2 signifies cognitively normal  
306 individuals with subjective complaints; GDS 3 signifies the earliest objective cognitive deficits  
307 equivalent to MCI; and GDS 4 signifies clear cut cognitive and functional deficits equivalent to  
308 mild dementia. GDS 5-7 designate moderate through severe stages of dementia.

309

310 *The Hopkins Verbal Learning Test-Revised* (HVL; 48) is a neuropsychological assessment tool  
311 used to assess verbal learning and memory. Participants are instructed to recall a list of 12  
312 noun-words over three trials. Total words correctly recalled across three trials (max 36). The  
313 number of correctly recalled words following a 20–25-minute delay (range 0-12) is used as a  
314 measure of free recall. The number of correctly identified words from the yes/no recognition task  
315 (range 0-12) is used as a measure of cue recognition memory.

316

317 *The Montreal Cognitive Assessment (MoCA (49))* is a widely utilized cognitive screening  
318 instrument designed to identify mild cognitive impairment. Cognitive domains assessed include  
319 Visuospatial/executive functions, language, memory attention, delayed recall and orientation.  
320 The MoCA has a total possible score of 30, with a score of 26 or above considered within a  
321 normal range, while scores between 18 and 25 are suggestive of MCI, and below 18 is  
322 suggestive of dementia.

323

324 *Number span - Forwards (50)* is used as a measure of simple auditory attention. Participants  
325 are presented with an increasing sequence of numbers over several trials and are required to  
326 repeat them back. The longest sequence correctly repeated is used as the measure of  
327 attentional capacity with a score range of 0-9.

328

329 *Number span – Backwards* is used as a measure of auditory working memory. Participants are  
330 asked to repeat number sequences in reverse order. The longest backward-repeated sequence  
331 is used as the measure of working memory with scores ranging from 0-8. For forwards and  
332 backwards span, higher scores denote better performance.

333

334 *Noise Pareidolia Task - Short Form (51)* is a neuropsychological assessment designed to  
335 evaluate an individual's propensity to perceive faces within ambiguous black and white patterns,  
336 offering insights into the phenomena of pareidolia and potential neurological or psychiatric  
337 implications of this perceptual bias. Following a practice trail, participants view multiple  
338 patterned items. For each, they respond to, "Do you see a face?", marking the perceived face's  
339 location if positive. Scoring categories include Correct Face Responses with a range of 0-7,  
340 indicating accurate identification of actual faces; Correct Noise Responses ranging from 0-13,  
341 denoting accurate rejection of patterns without faces; a Total Correct score combining the two  
342 previous scores with a range of 0-20; and Noise (Pareidolia) Responses, capturing incorrect

343 identifications of faces in noise-only patterns, with a possible range of 0-13. A high score  
344 indicates better perceptual discrimination, while frequent false positives (seeing faces where  
345 none exist) might point to a heightened propensity for pareidolia.

346

347 *The Animal Naming task* (52): This is used is a widely used measure to assess semantic  
348 fluency. Participants are asked to name as many different animals as quickly as possible within  
349 60 seconds. The total score represents the number of distinct animals named within the allowed  
350 time, and higher scores indicate better semantic fluency and retrieval ability.

351

352 *The 32-item Multilingual Naming Test* (MINT; 53) is a standardized instrument designed to  
353 quantify confrontation naming ability. Participants are presented with a set of 32 pictorial stimuli,  
354 each representing distinct objects, and are tasked to elicit the corresponding lexical  
355 representation. The MINT aims to assess lexical retrieval and object recognition capacities,  
356 integral elements of linguistic processing. Furthermore, the test's construct is curated to mitigate  
357 biases across diverse linguistic and cultural demographics. Scoring is systematic: each correctly  
358 identified stimulus contributes one point, culminating in a maximum possible score of 32, which  
359 is indicative of optimal linguistic processing capability.

360

361 *The Trail Making Test* (TMT; 54) is a widely recognized neuropsychological assessment used to  
362 examine cognitive flexibility, visual search, motor speed, and executive functioning. Comprising  
363 two main components, Trails A and B, the test evaluates both simple psychomotor speed and  
364 more complex task-switching abilities. Trails A requires participants to connect numbered circles  
365 (1-25) in ascending order as quickly as possible. The time taken in seconds to complete is used  
366 as a measure of processing speed. The max time to complete the test is 180 seconds. Longer  
367 completion times suggest poorer performances. Trails B is a widely used measure of task  
368 switching, cognitive flexibility, and executive functioning. In this task, participants are asked to

369 connect numbers and letters in ascending order (e.g., 1-A-2-B-3-C, etc.). The completion time in  
370 seconds is used as the outcome measure. The max time to complete the test is 300 seconds.  
371 Longer completion times suggest poorer performances.

372

373 *Number symbol coding (55)*: The NSCT is a brief measure of processing speed, attention, and  
374 working memory that can be completed by individuals into the moderate-to-severe stages of  
375 dementia. In the task, participants are typically required to match numbers with specific symbols  
376 within 90 seconds. Its streamlined nature allows for efficient administration. A score of 36 or  
377 below indicates cognitive impairment with possible scores ranging from 0-70.

378

379 *The AD8 (56)* is an informant-based interview designed to assess for signs and symptoms of  
380 dementia. The instrument is grounded in the principle that study partners (often close family  
381 members or friends) can provide crucial insights into an individual's cognitive and functional  
382 changes over time. The AD8 evaluates various domains, including memory, orientation,  
383 executive function, and interest in activities, through a series of eight questions. The study  
384 partner is asked to compare the individual's current cognitive and functional performance with  
385 their performance in the past. Responses indicating change consistent with cognitive decline  
386 are scored, with a higher score suggesting a greater likelihood of dementia. A score of 2 or  
387 more on the AD8 indicates that further dementia evaluation is warranted.

388

389 *The Clock Drawing Test (CDT (57))* is an established neuropsychological screening tool used to  
390 assess visuospatial abilities, executive functioning, and attention. This test requires participants  
391 to draw the face of a clock on a blank sheet of paper and then set the hands to a specified time,  
392 "10 minutes past 11." Scoring the CDT can range from a basic dichotomous "normal/abnormal"  
393 rating system that consider various aspects of the drawing, such as the presence and correct

394 sequencing of numbers, correct placement and proportion of the clock hands, and overall  
395 spatial organization.

396

397 *The Craft Story* (58) is a measure of verbal episodic memory. It consists of a short narrative that  
398 is read aloud to participants, who are then asked to recall as much information from the story as  
399 possible immediately after hearing it (Immediate Recall) and again after a specified delay  
400 (Delayed Recall), approximately 20 to 30 minutes later. Scoring is typically based on the  
401 number of thematic units (score range: 0-25) or specific details accurately recalled verbatim  
402 (score range: 0-44). Higher scores indicate better verbal learning and memory.

403

404 *The Benson Complex Figure Test* (BCFT; 59) is used to assess visuoconstructive skills, visual  
405 memory, and recognition. Participants begin by drawing a copy of a complex geometric figure  
406 ("copy" trial). After a delay of approximately 30 minutes, they are asked to redraw the figure  
407 from memory ("delayed recall" trial). Lastly, in the "recognition" trial, participants are asked if  
408 they recognize the figure from an array of figures with a yes-no response. Scoring is based on  
409 the accuracy and organization of drawings, types of errors in reproduction, and the accuracy of  
410 recognition. The BCFT is particularly useful for identifying cognitive deficits, especially those  
411 associated with right hemisphere dysfunctions. For the copy and delayed recall trial, a possible  
412 score of 0-17 can be obtained, with higher scores indicating better performances.

413

414 *Cognivue*® (60) is a computerized comprehensive cognitive assessment tool that evaluates a  
415 range of specific cognitive domains, including motor speed, visuospatial abilities, verbal and  
416 visual episodic memory, attention, executive functioning, and reaction time. Using adaptive  
417 psychophysics, it adjusts task difficulty in real-time based on participant responses. The  
418 assessment, which takes about 10 minutes, provides a numerical score categorizing  
419 performance as "normal," "mild impairment," or "moderate impairment." Cognivue® is Food and

420 Drug Administration (FDA)-cleared for use as an adjunctive tool to aid in assessing cognitive  
421 impairment in participants aged 55-95 years.

422

### 423 **Anxiety and depressive symptoms**

424 *The Hospital Anxiety and Depression Scale* (HADS; 61) is a validated instrument for screening  
425 symptoms of anxiety and depression in medically ill populations, specifically within non-  
426 psychiatric hospital contexts. The HADS encompasses 14 items, divided into two subscales: the  
427 Anxiety subscale (HADS-A) and the Depression subscale (HADS-D). Each item is appraised on  
428 a 4-point Likert scale, resulting in individual subscale scores that can range from 0 to 21.  
429 Interpretation of scores on both subscales is as follows: 0-7: Normal; 8-10: Borderline; 11-21:  
430 Abnormal. The HADS is recognized for its strong psychometric properties and has been  
431 employed extensively across various clinical cohorts.

432

433 *Depression, Anxiety, and Apathy Assessment (DA<sup>3</sup>)* is a 21-item questionnaire assessing how  
434 participants have felt and their experiences during the previous 2 weeks. Questions such as “I  
435 feel tense and unable to relax”, “I am able to get things started and completed”, and “I have  
436 trouble focusing my thoughts” are answered on a 4-point scale (0=rarely, 1=sometimes,  
437 2=often, or 3=always). Items are summed to provide a depression score (DA3-D, range: 0-7),  
438 an anxiety score (DA3-An, range: 0-7), and an apathy score (DA3-Ap, range: 0-7).

439

### 440 **Physical function assessment**

441

442 At baseline and each annual follow-up visit, HBI participants will undergo extensive  
443 performance-based physical functional assessments including body composition, muscle  
444 strength, balance, physical performance, and computerized gait analysis. Participants will be  
445 asked to come in wearing comfortable clothing and shoes and will start the physical functional

446 assessment with a series of body measurements (i.e., height, hip-, waist-, and neck-girth) taken  
447 with wall-mounted or handheld tape measures. Weight will be measured with InBody, a  
448 bioimpedance-based body composition analyzer, which provides estimates of weight, BMI,  
449 skeletal muscle mass, fat mass including visceral fat, intracellular and extracellular water  
450 content, basal metabolic rate, and other body composition indicators (InBody USA; 770 series).

451  
452 Muscle strength will be measured in the upper extremities with a Smedley Digital Hand  
453 Dynamometer (Baseline® Evaluation Instruments, Version 12-0286) for a total of three trials in  
454 each hand, with the average across the three trials used in data analysis. *Sarcopenia* status is  
455 reported using the Short Portable Sarcopenia Measure (SPSM) (62). The SPSM score ranges  
456 from 0-18, with lower scores indicating greater likelihood of sarcopenia.

457  
458 The mini-Physical Performance Task (mPPT) consists of 4 tasks: (1) Bending Over Test for  
459 which participants will be asked to bend over without bending their knees to pick up a binder clip  
460 placed about 1 foot from their foot on the dominant side; (2) a 50-foot timed walk task, (3) the 5  
461 Times Sit to Stand Test (5XSST) using a sturdy 4-leg non-rolling chair with hand support, with  
462 the participants asked to rise and sit down in the chair as fast as they can for a total of five times  
463 without using the armrests; and (4) the Progressive Romberg Balance Test (PRBT) for which  
464 participants are timed as they complete 10-second side-by-side, semi-tandem, and tandem  
465 balance tasks (63). The mPPT score ranges from 0-16 with higher scores indicating greater  
466 physical functionality.

467  
468 Participants will undergo a complex gait and balance evaluation on an electronic pressure-  
469 based walkway (Zeno Walkway™) and data processed using the ProtoKinetics Movement  
470 Analysis Software (ProtoKinetics, Version 6.00C1). The Zeno Walkway provides a wealth of  
471 temporal and spatial measures of gait associated with fall risk including velocity, cycle time, %

472 stance, step length, stride width, % swing, % single support, and other kinetic and kinematic gait  
473 parameters. The HBI protocol requires completion of a series of walking tests performed on the  
474 Zeno Walkway in the following sequence: (1) Single-task (walking at normal pace + no  
475 concurrent cognitive task); (2) Dual-task (walking + reciting the alphabet); (3) Dual-task (+ serial  
476 subtraction); and (4) Dual-task (+ texting) with parameter estimates derived for each of the four  
477 walks.

478

479 Balance and risk of fall also will be assessed with 1) Limits of Stability (LOS) and 2) Four  
480 Square Step Test (FSST). LOS measures how much an individual can lean in four directions:  
481 the mediolateral (left/right) and anteroposterior (forward/backward) directions/axes while  
482 standing with their feet shoulder width apart. LOS starts with the participant standing for 30  
483 seconds in quiet standing (QST) with their arms by their side with eyes open. Participants are  
484 then asked to lean forward as far as they can without taking a recovery step or falling, return to  
485 center, then lean left, return to center, lean backward, return to center, and finally lean right and  
486 return to center. While no specific amount of time holding the lean is required, the rater is  
487 assessing whether the lean is held for a minimum of 2 seconds. One trial is conducted for the  
488 LOS and QST tests, with one retake allowed. FSST is a dynamic test of balance and  
489 coordination which involves stepping as fast as possible in each of 4 squares with both feet in a  
490 predetermined sequence (64). Participants are allowed to practice one time before testing  
491 commences with one retake permitted in case of tripping or incorrect step sequence. Two trials  
492 are completed for FSST, with the better time (in seconds) being recorded as the score. Both  
493 LOS and FSST are conducted with the Zeno Walkway inertial sensor waist belt to capture trunk  
494 excursion.

495

496 Timed up and Go (TUG) is a timed assessment that requires a person to stand (handsfree) from  
497 a chair walk 3 meters and return to sitting (handsfree) (65, 66). It is considered a gold standard

498 indicating falls risk in older adults. Cognitive TUG i(TUG-Cog) is TUG with the addition of a  
499 cognitive task such as serial subtraction (e.g., subtract 87 by 3).

500

501 Kinetisense is a markerless motion capture analysis system that uses infrared cameras to  
502 identify the kinematics of moving joints (67, 68). It provides real-time biofeedback on the  
503 performance of balance, gait, and functional activities in coronal, sagittal, and transverse  
504 planes. Kinetisense produces video playback and generated reports that include a risk of fall  
505 gait assessment that is calculated based on normative gait parameters and when combined with  
506 other gold standard physical performance assessments such as the TUG and STSX5, provides  
507 ergonomic feedback of a person's overall function and balance.

508

509 Three global measures of frailty are determined at each visit. The Rockwood Frailty Index (69),  
510 the Fried Frailty Phenotype (70), and the CHSA Clinical Frailty Scale (71). Higher scores on the  
511 frailty scales are suggestive of greater likelihood of being frail.

512

### 513 **Blood- and saliva-based biomarkers and genetics**

514

515 A custom panel of tests (i.e., Healthy Brain Initiative (HBI) Profile) will be conducted. At the start  
516 of the core visit, blood will be drawn from each participant by venipuncture by trained  
517 phlebotomists. Participants also provide saliva samples for DNA extraction and APOE e4  
518 carrier status. Saliva will be obtained through self-collection kits. The collected specimens will  
519 be processed and used to evaluate plasma biomarkers, genetic data, and metabolic panels, and  
520 then stored in a biorepository for future research as plasma, whole blood, and DNA. Measures  
521 collected include a comprehensive metabolic panel, cortisol, cystatin C, hemoglobin A1C,  
522 insulin resistance, homocysteine, high-sensitivity C-reactive protein (hs-CRP), a complete lipid  
523 panel with particles, thyroid stimulating hormone, vitamin B12, folate, vitamin D, apolipoprotein

524 E (APOE) e4 status, and multiple plasma ADRD biomarkers (e.g., Ab42, Ab40, p-tau). Blood  
525 specimens will be processed in HBI's lab for shipment to C2N laboratories for analysis. C2N  
526 employs mass spectrometry to calculate multiple plasma AD biomarker values including  
527 Ab42/40, p-tau181, p-tau217, and p-tau/np-tau. Additionally, the HBI lab conducts in-house  
528 measurements of biomarkers such as neurofilament light (NFL), glial fibrillary acidic protein  
529 (GFAP), and TAR DNA-binding protein 43 (TDP-43) on Quanterix SIMOA™ platforms for each  
530 participant.

531

### 532 **Machine-based assessments**

533

534 *Optical coherences tomography* (OCT), an imaging technique using near-infrared light to  
535 capture detailed images of the cornea, lens, retinal tissue, anterior chamber, and retinal  
536 vasculature, is an emerging technology in ADRD research. The retina is embryologically derived  
537 from the same tissue as the cerebral cortex, and pathological changes in cortical gray matter  
538 appear in the retina as well, including deposits of amyloid- $\beta$  revealed using targeted tracers (72,  
539 73). Retinal measurements include the central subfield thickness, the volume and thickness of  
540 the macula, the thickness of the retinal nerve fiber layer, internal plexiform layer thickness, and  
541 the ganglion cell layer thickness. The minimum thickness of both the ganglion cell layer and the  
542 internal plexiform layer is also collected and is strongly associated with various cognitive  
543 domains and the CDR sum of boxes along with the combined ganglion cell layer and internal  
544 plexiform layer thicknesses (74). By collecting these data in HBI, we aim to explore the use of  
545 these markers in determining current impairment through non-invasive imaging procedures as  
546 well as identifying risk of future impairment based on the health of retinal tissue (75-77).

547

548 *Neurobehavioral markers*, including gaze behavior and speech behavior, have been shown to  
549 identify longitudinal changes in prodromal dementia, with some research showing an ability to

550 identify preclinical impairment through the examination of connected speech production (78-80).  
551 Gaze behavior assessed through eye movements during cognitive assessment tasks further  
552 capture differences between not only cognitively normal participants and impaired participants  
553 through the examination of exploratory behavior and novelty preference, but differentiation of  
554 likely cause of impairment including separating DLB and PD from AD using saccadic behavior  
555 (75, 81, 82). Eye movements are collected using Tobii Pro eye trackers, including the Tobii  
556 Dynavox and the Tobii Pro Spectrum, and audio metrics including speech are collected using  
557 hypercardioid directional microphones for reducing extraneous background noise. These  
558 markers are collected while picture description, narrative recall, and visual search tasks are  
559 administered to participants using custom-designed experimental software written in Python and  
560 C++.

561

562

563

#### 564 **Neuroimaging procedures and measures**

565

566 *MRI*. All participants will have brain MRI scans using a GE 3 Tesla 750W scanner at baseline and  
567 every 2 years. We will collect high-resolution 3D sagittal Magnetization-Prepared Rapid Gradient-  
568 Echo (MPRAGE) images with axial and coronal reconstructions to quantitate brain atrophy. We will  
569 use axial 3DT2 FLAIR and 2D T2\* brain images to quantify white matter hyperintensities (WMH),  
570 infarcts, microhemorrhages and superficial siderosis. We will collect diffusion-weighted images  
571 (diffusion tensor imaging) to measure mean diffusivity and fractional anisotropy to estimate  
572 microstructural integrity and white matter tractography. Last, we will collect resting BOLD  
573 sequences for functional MRI analyses. The total imaging time sequences is estimated to be 45  
574 minutes. The MRI sequences selected for this project are modified from the ADNI-3 canonical  
575 protocol and were selected to enhance compatibility with national efforts (83).

576

577 In addition to visual reads for MRI scans, post-processing of all MRI images will be performed  
578 according to ADNI procedures, including correction for geometric distortion of gradient nonlinearity,  
579 field inhomogeneity correction, histogram-peak sharpening, and correction for site-specific scanner  
580 features/field strength. Cortical, subcortical, ventricular, and white matter hyperintensity volumes  
581 are analyzed using Combinatics® cNeuro Suite, an FDA-cleared quantitative pipeline. Automated  
582 brain imaging quantification using artificial intelligence (AI) technology offers many opportunities  
583 to reduce the time needed for imaging analysis and increase the accuracy, precision,  
584 consistency, robustness, and, as a consequence, the research quality of the data. Combinostics  
585 cMRI suite is comparable to manual segmentation with Pearson coefficients ranging from 0.84  
586 to 0.99. The cMRI suite contains important dementia biomarkers including hippocampal, inferior  
587 lateral ventricle, cerebral white and gray matter, cerebral cortex, and medial temporal lobe  
588 volumes, and a global cortical atrophy index with an 85% sensitivity and 86% specificity. White  
589 matter integrity and myeline measures will be conducted using Synthetic MRI®, an FDA-cleared  
590 AI pipeline providing quantitative measurements of intracranial, brain parenchyma, myelin,  
591 cerebrospinal fluid volumes and brain parenchymal and myelin correlated fractions.

592

593 *PET*. Participants who consent will have baseline amyloid PET scans with ligands from Life  
594 Molecular Imaging. Non-contrast enhanced computerized tomography (CT) is used for  
595 attenuation correction of the PET images and for morphological localization through image  
596 fusion between PET and CT. PET scans will be processed using the reconstruction algorithm  
597 provided to include attenuation correction with an image matrix size of 128 x 128, and a  
598 transaxial pixel size of 2-3 mm. Participants will undergo an amyloid PET scan using Neuraceq™  
599 (F18 Florbetaben injection), an amyloid PET ligand that received FDA approval in March 2014.  
600 8.1 mCi +/- 20% of Neuraceq will be administered as a single bolus intravenous injection at a  
601 rate of 6 seconds/mL in a total volume of up to 10 mL. Approximately 10 minutes prior to the

602 initiation of the PET scan, the participant will be positioned in the PET scanner. The head will be  
603 positioned such that the entire brain including the cerebellum will be in the field of view (FOV).  
604 An attenuation correction image will be acquired following standard procedures. PET imaging  
605 will commence 90 min post injection for a total of 20 min (4 x 5 min frames). SUVR images will  
606 be created using 90 min after injection and used for qualitative reads and to extract global  
607 values. The Combinostics cPET® suite provides a segmental analysis of FDG and amyloid PET  
608 with regional and global SUVRs and for amyloid PET calculates the Centiloid Level.

609

### 610 **Data and biospecimen repository**

611

612 The data repository will consist of clinical, cognitive, behavioral, and functional data as well as  
613 summary data from plasma, DNA, and imaging biomarker studies that will be kept in both paper  
614 and electronic form and kept in locked cabinets within locked offices and compiled in a REDCap  
615 electronic database accessible via protected passwords. The database will contain all data  
616 derived from interviews of participants and study partners, neuropsychological and physical  
617 performance assessments, medical exams, as well as summaries of blood and imaging data.  
618 Physical records of neuroimaging studies will be placed in participant files kept in locked file  
619 cabinets and summary results will be kept in a separate protected electronic file.

620

621 Blood specimens are processed in the lab for shipping to commercial laboratories for analysis  
622 and for storage in -80°C freezers located in the lab (with generator backup). Buffy coat will be  
623 extracted from blood for future DNA studies. All specimens collected will be stored in the CCBH  
624 laboratory refrigerator and freezers, which are only accessible by CCBH laboratory personnel.  
625 The specimens will be kept indefinitely.

626

627 Biological samples will be sent to the National Centralized Repository for Alzheimer’s Disease  
628 and Related Dementias (NCRAD) for sharing with other investigators. NCRAD is a national  
629 resource supported by the National Institute on Aging (NIA) that prepares and stores biological  
630 specimens from all over the world and makes them available to approved scientists who would  
631 not otherwise be able to access this material. Biological samples will be de-identified and  
632 maintained in the CCBH laboratory indefinitely. These biological samples allow for studies of the  
633 causes of many diseases, including ADRD.

634

### 635 **Primary HBI outcomes**

636

637 The primary outcome of HBI is to improve our understanding of what healthy brain aging is, and  
638 how to best detect the earliest signs of MCI/ADRD in diverse populations. This is accomplished  
639 via deep phenotyping, biomarker collection, and genetic (including epigenetic) markers. This  
640 work has allowed us to develop the brain health platform (described below) and leverage the  
641 ATN framework to begin to take a precision medicine approach to brain health and ADRD  
642 detection, and eventually treatment and prevention.

643

644 *Brain health platform.* The Brain Health Platform (84) quantifies brain health and identifies  
645 ADRD risk factors based on 3 measures collected that will be collected at HBI: Resilience Index  
646 (RI) (85), the Vulnerability Index (VI) (86); and the Number-Symbol Coding Task (NSCT) (55).  
647 VI and RI scores (range: 2-20 and 1-378, respectively) are calculated from demographics,  
648 lifestyle questionnaires, physical assessments, medical history, and neuropsychological  
649 examination. Details of the Brain Health Platform including the VI and RI are published  
650 elsewhere (85, 86). By combining measures of performance, resilience, and vulnerability, it  
651 provides an overall snapshot of the participant’s brain health at a given visit. Instead of a

652 summary score, the platform indicates whether participants are at low, intermediate, or high risk  
653 of being cognitively impaired.

654

655 *ATN Staging.* Once a sufficient number of individuals have completed MRI, amyloid and tau  
656 PET, and plasma ADRD biomarkers, we will use the distribution of values within the normal  
657 control group to z-score individual participants and provide categorization consistent with the  
658 ATN (amyloid tau neurodegeneration) research framework (13). Given the bimodal and global  
659 distribution of amyloid PET data, Gaussian mixture modeling will be used to identify A- and A+  
660 distributions. Categorization of Tau PET into Braak III and above will be used to classify  
661 individuals as T- or T+ and hippocampus volume will be used to classify individuals as N- or N+.  
662 This will be matched to plasma Ab40, Ab42 (A- and A+), Tau and p-tau (T- or T+), and NFL (N-  
663 or N+). Further, we can consider other pathologies in the form of MRI white matter  
664 hyperintensities for vascular disease (V- or V+), plasma alpha synuclein and phospho-synuclein  
665 for Lewy body pathology (S- or S+), and plasma TDP-43 (P- or P+). This will permit testing of  
666 the ATN framework in a systematic fashion in a deeply phenotyped cohort.

667 *Clinical diagnoses.* A clinical diagnosis of the participant's cognitive status (normal cognition,  
668 MCI, or dementia) and their ADRD etiological diagnosis (e.g., Alzheimer's disease or Lewy body  
669 disease) is determined via consensus conference of the HBI clinicians. To make the diagnosis,  
670 clinicians review the neuropsychological test findings and supporting clinical data independent  
671 of the biomarker data and follow consensus criteria guidelines (2, 3, 87-90).

672

### 673 **Intermediary/secondary outcomes**

674

675 Beyond the ATN framework, Brain Health Platform, and clinical diagnoses, which capture  
676 presence of disease or risk of developing disease, continuous measures of the ADRD

677 biomarkers and functional and cognitive test scores (e.g., longitudinal change in plasma  
678 Ab42/40, frailty scores, or executive function over time) will serve as intermediary outcomes.

679

## 680 **Novel approaches in the HBI**

681

682 *Precision medicine.* Precision medicine is a model that permits the separation of patients into  
683 different groups to better inform and tailor medical decisions, practice, and treatment to defined  
684 subgroups based on their (a) predicted responses and/or (b) risk of disease (91-93). Precision  
685 medicine approaches can help shift medical practice from reaction to prevention, predict  
686 susceptibility, improve early detection, and eliminate trial and error treatment thereby avoiding  
687 or limited negative side effects and maximizing efficacy (94). Commonly used in oncology,  
688 precision medicine has expanded to other fields. Precision medicine approaches are typically  
689 genome-based using tissue markers acquired via biopsy or genetic markers in blood. In the  
690 case of ADRD, biopsy is not a viable path and genetic causes of disease are limited. Instead,  
691 HBI has focused on deep phenotyping individuals to examine small deviations from normal or  
692 expected structure, function, and behavior. Using this detailed and comprehensive picture, HBI  
693 will better characterize factors that make individuals (a) more likely to develop disease (i.e.,  
694 vulnerability) or less likely to develop disease (i.e., resilience) (95, 96).

695

696 *Machine learning.* Given the vast quantities of data generated through the HBI, machine  
697 learning techniques become viable and, in some cases, preferable compared to more traditional  
698 statistical techniques of data analysis. Model generation using supervised learning techniques,  
699 including both classification and regression, enables hypothesis testing of diagnostic and  
700 screening techniques, leading to developments such as multi-stage screening systems and the  
701 identification of markers associated with early-stage and prodromal cognitive impairment

702 including groups of cognitive assessments as well as markers of vulnerability and brain health  
703 (84, 86, 97, 98).

704

705 *Geospatial data and the exposome.* HBI will collect residential addresses and self-reported  
706 environmental exposures and behaviors from various time points during the participant's life  
707 course from childhood to later life. These data will address HBI's specific aim to determine how  
708 sociodemographic and lifestyle factors contribute to risk for and resilience against ADRD. HBI's  
709 life course measures will target key domains of the exposome, which has been defined as the  
710 "exposures of an individual in a lifetime and how those exposures relate to health" and  
711 encompasses all non-genetic determinants of health (99). Domains to be captured in HBI center  
712 on "general external" exposome measures of social context (e.g., participant's and  
713 neighborhood SES) and the neighborhood built environment (e.g., greenspaces, sidewalk  
714 availability), as well as "specific external" exposome measures encompassing lifestyle behaviors  
715 (e.g., diet, exercise, medication use). The measures will either be collected via self-report by the  
716 participant or study partner or will be derived by geocoding addresses to identify the latitude-  
717 longitude and/or Census tract location and linking to built and social environment data from  
718 sources such as the US Census, the Neighborhood Atlas (100), and satellite imagery from the  
719 US Geological Survey (101).

720

721 *Epigenetics.* DNA methylation (DNAm) is an epigenetic modification where a methyl group  
722 attaches to DNA's cytosine nucleotides, often at CpG sites (102). This process can vary with cell  
723 type, developmental stage, and environmental conditions (103, 104) has emerged as a pivotal  
724 biomarker of biological aging, with its profiles often referred to as "epigenetic clocks" (105).  
725 These clocks hint at disparities between chronological and biological age, with greater than  
726 expected biological ages associated with increased risk for neurodegenerative disease and  
727 earlier mortality (105-107). Specific lifestyle risks, such as hypertension (108, 109) and obesity

728 (110), correlate with distinct DNAm changes in genes governing vascular function,  
729 neuroinflammation, and cognition (111, 112). In essence, DNAm may offer a potential pathway  
730 through which cognitive health disparities may arise.

731

732 Our objective for collecting DNAm data will be to improve and refine current epigenetic age  
733 clocks to brain aging while also seeking an in-depth investigation of associations between  
734 DNAm profiles and various lifestyle factors. This endeavor is geared towards a comprehensive  
735 understanding of the relationship between DNAm alterations and brain health, with a focus on  
736 the molecular determinants underpinning aging processes. Whole blood samples (10 mL) from  
737 HBI participants will be used for DNAm data extraction. DNAm extraction will be performed  
738 using the Infinium Methylation EPIC BeadChip 850k platform the Center for Genome  
739 Technology at John P. Hussman Institute for Human Genomics, University of Miami Miller  
740 School of Medicine. Using these data, our objective is to construct refined epigenetic clocks that  
741 provide enhanced precision in estimating biological age and its divergence from chronological  
742 age.

743

744 *Transdisciplinary and multidisciplinary study team approach.* The HBI team was purposefully  
745 constructed to be multidisciplinary and transdisciplinary, including individuals from varied  
746 disciplines who continuously collaborate, infusing conceptual knowledge and methodologies  
747 unique to each discipline to inform not only the cohort study protocol but also in the methods,  
748 analyses, and means of reporting results when addressing the HBI's specific aims. The  
749 multidisciplinary team includes physicians, nurse practitioners, nurses, social workers, physical  
750 therapists, gerontologists, cognitive neuroscientists, biostatisticians, bioinformatic analysts,  
751 molecular scientists, data scientists, geographic information system specialists, and an urban  
752 planner. The HBI team structure and personnel expertise/skills will be modified as needed to  
753 increase efficiency and accommodate new research initiatives.

754 **Data management plans and data security**

755

756 Data management is handled by the CCBH Data Core, which includes a Data Manager, Data  
757 Scientists, and trained data entry personnel. CCBH uses a multimodal data collection approach  
758 that includes both paper (e.g., neuropsychological battery) and electronic sources (e.g.,  
759 participant and study partner questionnaires). Paper sources are scanned and entered in  
760 REDCap, an electronic data capture and management system offered through the University of  
761 Miami Miller School of Medicine. Access to REDCap via password and restricted to CCBH Data  
762 Core staff. Participant and study partner questionnaires are distributed via email to individual  
763 study participants and accessed via REDCap-generated questionnaire link, with completed  
764 questionnaires saved directly in REDCap. Select parameters from machine (e.g., OCT, Zeno  
765 Walkway) and lab and imaging (e.g., MRI, PET) reports are entered in REDCap with full reports  
766 stored on University of Miami approved and backed-up shared drives.

767

768 REDCap is managed by the University of Miami Biomedical and the Health Research  
769 Informatics Core, a secure, private cloud and isolated network infrastructure. This isolated  
770 health network is protected by an independent firewall; remote access is provided by a Virtual  
771 Private Network (VPN). Data security is assured by Virtual Routing Forwarding (VRF); 2Factor  
772 VPN authentication; 10 Gbps Juniper Firewall; Web Proxy Security; Load Balancer; Dell XC  
773 Web-Scale Converged Appliances running Windows Hyper-v with Azure; Desktop Virtualization  
774 with Desktop connections; and Disaster Recovery. The VRF is an isolated, protected network  
775 perimeter that enforces the necessary security and compliance restrictions needed to protect  
776 data from external threats.

777

778 All precautions to protect the integrity of the data are taken and any unauthorized access will be  
779 reported to the University of Miami Institutional Review Board. To minimize risk, all materials are

780 kept in locked file cabinets (paper sources) and secure servers (electronic sources), which are  
781 only available to the research team members. Data shared outside of the study team is de-  
782 identified prior to distribution using a unique participant code identifier. The CCBH laboratory  
783 has restricted access to personnel. Samples collected are processed immediately and sent out  
784 for analysis. Excess blood is stored in the CCBH laboratory refrigerator and freezers indefinitely,  
785 according to current standard operating procedures.

786

### 787 **Safety considerations**

788

789 This observational cohort study does not meet the definition of a clinical trial and an external  
790 Data Safety Monitoring Board is not required. Despite all precautions, medical complications  
791 may occur and any adverse events will be reported to the IRB. These include not only physical  
792 injury, but also possible psychological, social or economic harm, discomfort, inconvenience, or  
793 breach of confidentiality. To minimize risk, all study materials are kept in locked file cabinets and  
794 only available to investigators and research personnel associated with the study. In the event of  
795 an adverse effect, medical personnel are available with access to an emergency room. For the  
796 standard clinical examinations, there are minimal to no risks associated with testing. The main  
797 risk is loss of privacy, and every precaution is taken to ensure confidentiality. We are sensitive  
798 to disclosure of examination results; this will be performed in private with feedback including  
799 medical referrals and follow-up provided to participants. All precautions to protect the integrity of  
800 the data repository and registry will be made and any unauthorized access will be reported to  
801 the University of Miami Miller School of Medicine IRB.

802

803 Following the feedback session, participants can be referred to CCBH clinical practices for  
804 clinical evaluation and follow-up. There are no inherent risks associated with the physical,

805 neurological, or psychiatric exams other than discovering a condition that was not previously  
806 known. Specific HBI procedures have specific risks as described below:

807

808 • To reduce the risk of loss of balance and falling, functional testing will be performed by  
809 research staff trained by a physical therapist with advanced expertise (DPT). There is a  
810 potential risk in self-collected saliva, of coming into contact with the stabilizing fluid  
811 located in the test tube. Users may experience eye and/or skin irritation. User  
812 instructions provide warning and how to obtain guidance for handling accidental contact  
813 with the stabilizing fluid. The potential risks of blood drawing may occasionally include  
814 pain, bruising, fainting, or a small infection at the puncture site. Indications of procedure  
815 to follow in case of any of these will be provided to the participants.

816

817 • MRI scanning involves the use of a magnet and radio frequency energy. Individuals who  
818 have implanted devices, such as pacemakers, certain aneurysm clips, shrapnel,  
819 defibrillators, cochlear/ear devices, deep brain stimulators, spinal cord monitoring  
820 devices, or metal in the eye or skull are at risk. Therefore, before the procedure, each  
821 candidate will be pre-screened for presence of absolute and relative contraindications.  
822 Presence of absolute contraindications will disqualify participants from the MRI  
823 procedure, while presence of relative contraindications will warrant a careful weighting of  
824 risks against benefits for the participant. Those cleared for the procedure will be  
825 instructed to remove all metallic objects prior to entering the MRI room. In the case of a  
826 medical emergency, trained personnel will follow their respective MRI Emergency  
827 Procedures Protocol, which entails calling 911, transferring the participant out of the  
828 magnetic field area, and providing basic life support by the radiologist, if necessary, until  
829 emergency service arrives. Procedures are also described for situations when an

830 emergency stop is required, a magnet emergency occurs, or other unexpected events  
831 (e.g., power outages) emerge.

832

833 • The risks associated with PET scans will be discussed with the participants prior to them  
834 undertaking the procedure. They include exposure to a radioactive ligand and local site  
835 injection reactions. The most common adverse reactions are injection site erythema  
836 (1.7%), injection site irritation (1.1%) and injection site pain (3.4%). It is not known  
837 whether Neuraceq can cause fetal harm (Pregnancy Category C) so women of  
838 reproductive potential will be required to have a pregnancy test (paid for by the study) to  
839 assess pregnancy status prior to administration. Pregnant women are excluded from  
840 participating in this component of the study. PET compounds, such as Florbetaben F18  
841 (Neuraceq), use small amounts of radiation to generate images. Everyone receives a  
842 small amount of unavoidable radiation each year. Some of this radiation comes from  
843 space and some from naturally occurring radioactive forms of water and minerals. Each  
844 Florbetaben F18 scan has a radiation dose equivalent to about 1.6 years' worth of  
845 natural radiation (approximately 5.8 millisievert or mSv). The use of a CT scan to  
846 calculate attenuation correction for reconstruction of Neuraceq images (as done in  
847 PET/CT imaging) will add radiation exposure. Diagnostic head CT scans using helical  
848 scanners administer an average of  $2.2 \pm 1.3$  mSv effective dose (CRCPD Publication E-  
849 07-2, 2007). The actual radiation dose is operator and scanner dependent. Thus, the  
850 total combined radiation exposure from Neuraceq administration and subsequent scan  
851 on a PET/CT scanner is estimated to be 8 mSv.

852

853

854

855

856 **Sample size/power and planned statistical analyses**

857

858 *Sample size and power.* HBI encompasses multiple aims (described further above), and  
859 therefore varying statistical approaches and sample sizes will be involved depending on the  
860 research question at hand. Diagnostics will be conducted to assess for non-linearity, missing  
861 data, and other issues (e.g., multicollinearity) and adjustments will be made to the analyses as  
862 necessary (e.g., multiple imputation).

863

864 The HBI was originally built off and thus devised to accommodate planned analyses for a grant-  
865 funded study on “Multicultural Community Dementia Screening” (MCS) (NIH/NIA  
866 R01AG040211). The MCS study was designed to evaluate transition in cognitive status  
867 according to NIA-AA stages. For that study, we calculated that we would need a sample of 500  
868 participants to give us a representative sample across racial and ethnic strata, sex, and NIA-AA  
869 stages I-IV. This works out to approximately 100 individuals for each of the 5 cognitive states  
870 (e.g., normal cognition, subjective cognitive decline, etc.). To maintain 80% power for Black  
871 participants based on the desired racial/ethnic distribution (80% White, 20% Black; 35%  
872 Hispanic), we will need at least 100 (20% with 95% C.I. 82 - 118) for a minimum prevalence rate  
873 of 28%.

874

875 *Statistical analyses.* The MCS study aims to detect longitudinal decline and transition across  
876 NIA-AA stages using the baseline measures and develop a predictive model for identifying  
877 individuals at high risk to transition between NIA-AA stages. Several statistical approaches will  
878 be used to characterize longitudinal changes within a multicultural community-based cohort to  
879 determine whether baseline demographic, functional, genetic, and medical characteristics  
880 predict changes in cognition from baseline during annual evaluations. The progression of  
881 prevalence rate changes from baseline to 12, 24, and 36 months of follow-up will be calculated with

882 95% CI using Clopper-Pearson interval (113). During planned follow-up, we estimate that  
883 approximately 5% of cognitively normal participants aged 55-65, 10% of cognitively normal  
884 participants aged 65-75, and 40% of cognitively normal participants aged 75+ at baseline will  
885 transition to some form of cognitive impairment (114). We conservatively estimate a 15%  
886 attrition rate based on published rates (115) – this is higher than our experience with prior  
887 cohorts (~10%).

888

889 For longitudinal cognitive decline and transition across NIA-AA stages, we will use generalized  
890 linear mixed effect (GLME) models to compare the baseline diagnostic groups on rate of decline  
891 in cognitive performance. GMLE models also allow the assessment of change in continuous  
892 outcomes measure at multiple time points, modeling both fixed and random effects, and  
893 flexibility handling missing data. The impact of baseline cognitive status on the cumulative odds  
894 of being cognitively impaired (SCI, MCI and ADRD) versus being cognitive normal in the end of  
895 last follow-up will be assessed by the proportional-odds cumulative (POC) logit model,  
896 commonly used for ordinal data. Under the proportional odds assumption, we assumed that the  
897 effect estimated between each pair of outcomes across two response levels are the same so we  
898 will test the proportional odds assumption for model appropriateness. Covariates such as SES,  
899 demographics, biomarker, imaging, and genetic risk factors for identifying observed transitions will  
900 be tested and evaluated in the model. Since there are a large number of variables will be involved in  
901 the model, we will apply Benjamini and Hochberg procedure to account for the multiple  
902 comparison issue to keep the type I error  $\alpha=.05$  (116). For assessing NIA-AA stage transitions  
903 over the study period (e.g., normal to SCI, normal to MCI, MCI to mild ADRD), we will use the  
904 ordinal logistic Markov chain transition model, an extension of the POC model, which considers  
905 intermediary transition for equal space data with more than two response variables with the  
906 assumption that the conditional distribution of the outcome at time point T only depends on the  
907 state at previous time point T-1. A stepwise regression with covariates sex, racial/ethnic group

908 and age will be used to select the predictive covariates from longitudinal cognitive, fluid, genetic,  
909 and imaging biomarker results to predict the longitudinal decline and transition across NIA-AA  
910 stages. The final model will include all significant ( $p$ -value $<.05$ ) independent variables,  
911 interactions, and all pre-retained variables such as sex (to obtain the sex-adjusted odds ratios  
912 and 95% CI, along with risk differences) and age effect in cognitive impairment. We will vary  
913 covariance matrices to derive the best model with the lowest Bayesian Information Criterion  
914 (BIC). If models do not converge, we will use generalized estimating equation (GEE) with  
915 covariance matrices.

916

917 Understanding how risk factors work together and developing a predictive model for identifying  
918 high-risk individuals is one important aim of this proposal (117, 118). However, age is not only  
919 the strongest risk factor for ADRD but is also the strongest risk factor for death. Since the  
920 mortality rate in this cohort is not ignorable, we may consider a discrete time competing risk  
921 model via generalized additive regression. It is clear that the conversion risks from normal to  
922 MCI and from MCI to ADRD increases sharply after the age 80. Thus, once all the coefficients  
923 and functions of the regression models are estimated, we will construct the transition probability  
924 matrix considering age among the cognitively normal, cognitively impaired (MCI/ADRD), and at  
925 death. We will also test for back conversion from MCI/ADRD to normal and from ADRD to MCI.  
926 This probability matrix can then be used to estimate the future conversion risk for an individual  
927 as well as the future composition of normal, MCI, and ADRD participants in a group of  
928 participants. Cognitive progression models can be constructed by using the multi-state Markov  
929 models with two competing absorbing states: MCI/ADRD and death, this is the commonly used  
930 model with three states: normal, MCI/ADRD and death, so the transition probability matrix are  
931 permitted from normal to MCI/ADRD, MCI/ADRD to death, normal to death, and MCI/ADRD to  
932 normal (117, 118).

933

934 **Ethical considerations and declarations**

935

936 HBI has been approved by the University of Miami Miller School of Medicine Institutional Review  
937 Board. Participants will provide informed consent at baseline and will be re-consented as  
938 needed with protocol changes.

939

940 **Timeline of the study**

941

942 HBI began recruiting participants in 2022. As of September 21, 2023, 156 participants have  
943 completed their baseline visit and a growing number of participants are being seen for their first  
944 follow-up visit. Enrolled participants are expected to be seen annually until the point at which  
945 they display moderate to severe ADRD symptoms and are no longer able to complete the  
946 evaluations, at which point they will be discontinued from the study. HBI is designed to be an  
947 ongoing, longitudinal cohort that recruits at least 500 participants and then maintains that  
948 sample size by refreshing the cohort to counteract any participant drop out.

949

950 **DISCUSSION**

951

952 HBI is planned as an ongoing, longitudinal observational cohort study of brain health among 500  
953 racially/ethnically diverse participants with no or mild cognitive impairment living in the South  
954 Florida region. It is differentiated from other cohorts of brain health and ADRD in its deep  
955 phenotyping and collection of a host of novel predictors (e.g., neighborhood social determinants  
956 of health, epigenetics) of risk for and resilience against ADRD and cognitive decline measured  
957 over the life course, in characterizing and validating new ADRD (e.g., neurobehavioral)  
958 biomarkers, and in employing unique approaches and methods (e.g., machine learning,  
959 transdisciplinary, exposome, etc.). Standardized questionnaires and assessments used across

960 multiple grant funded projects ensures comparability of measures and pooling of data that will  
961 permit high powered studies, which is particularly important for studies such as those examining  
962 effect measure modification that require large sample sizes. The cohort study will be significant  
963 in not only identifying modifiable factors that can be targeted via interventions to promote brain  
964 health and reduce ADRD risk, but also in its creation of a data and biospecimen repository, that  
965 can be shared in collaboration with the larger research community.

966

967 HBI's limitations include a potential lack of generalizability of findings to certain communities  
968 and groups. Commonly, research volunteers tend to be more educated and less diverse than  
969 the general population and socioeconomically disadvantaged populations can be harder to  
970 retain in longitudinal cohort studies. Targeted recruitment efforts will be made to ensure a  
971 diverse group of participants are enrolled, including regular talks and events (e.g., health  
972 screenings) in communities that are representative of the diversity HBI aims to achieve. CCBH  
973 has begun building relationships with diverse communities in the South Florida area and plans  
974 to expand upon and support these relationships to develop an awareness of CCBH and to  
975 develop trust with local communities. Various retention efforts will be employed such as regular  
976 newsletters, telephone follow-up calls in between the annual visits, and sending birthday cards  
977 to participants. Transportation costs are covered for individuals who have no other means of  
978 traveling to CCBH to complete their HBI visits.

979

980 The expansive nature of the data collected at each annual visit places some burden on  
981 participants' time, which could also affect retention. The CCBH team regularly weighs the utility  
982 of the data being collected in fulfilling HBI's goals against participant burden. When needed,  
983 adjustments are and will be made to questionnaire forms, assessments, or the order of visit  
984 activities to minimize burden and/or incorporate new research questions.

985

986 The goal of recruiting and maintaining a steady cohort of 500 participants involves forethought.  
987 CCBH works to ensure it has the resources, staff, and scheduling time required to achieve this  
988 recruitment goal, including availability of ample facility spaces to conduct the visits and  
989 individuals who are cross-trained in multiple assessments to cover staff who are out of the  
990 office. The structure and timing of visits are designed to ensure the maximum number of  
991 participants can be seen over a given week, and a Clinical Trial Management System will be  
992 implemented to efficiently track all visits, reminder calls to participants, schedule staff time,  
993 supplies, and the like. New staff and additional research space will be acquired as needed to  
994 meet the recruitment sample size goals.

995

996 Findings from HBI will be disseminated broadly in a variety of formats. Results will be presented  
997 at academic conferences; at community events; and at local, national, and international  
998 seminars/presentations; and findings will be published in peer-reviewed journals. Newsworthy  
999 findings will be broadcast via press releases to the University of Miami media office and local  
1000 and national print and other media sources. In addition, highlights from the study will be  
1001 included in our regular newsletter for participants.

1002

1003 In summary, HBI is poised to make substantial contributions to the growing field of research on  
1004 brain health and risk and resilience factors associated with ADRD. The data collected will lead  
1005 to breakthroughs in developing new diagnostics and therapeutics, create comprehensive  
1006 diagnostic evaluations, provide the evidence base for precision medicine approaches to  
1007 dementia prevention with individualized treatment plans, provide educational and training  
1008 opportunities, and create information clearinghouse activities for participants, families,  
1009 caregivers, the lay public, health professionals, and policy makers.

1010

1011 **Author contributions**

1012 Dr. Besser: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing;

1013 Dr. Chrisphonte: Writing – Original Draft Preparation, Writing – Review & Editing; Dr. Kleiman:

1014 Writing – Original Draft Preparation, Writing – Review & Editing; Dr. O’Shea: Writing – Original

1015 Draft Preparation, Writing – Review & Editing; Dr. Rosenfeld: Writing – Original Draft

1016 Preparation, Writing – Review & Editing; Dr. Tolea: Writing – Original Draft Preparation, Writing

1017 – Review & Editing; Dr. Galvin: Conceptualization, Writing – Original Draft Preparation, Writing –

1018 Review & Editing, Supervision.

1019

1020 **Acknowledgements**

1021 The Healthy Brain Initiative is supported by NIH *R01AG071514, R01AG071514S1,*  
1022 *R01NS101483, R01NS101483S1, RF1AG075901, and R56AG074889.* HBI would not be  
1023 possible without the support of the Comprehensive Center for Brain Health's staff and  
1024 postdoctoral fellows: Katherine Almonte, Mirza Baig, Andrea Buehler, Yolene Caicedo, Simone  
1025 Camacho, Gabrielle Czerwonko, Iris Cohen, Shanell Disla, Reem Ezzeddine, Conor Galvin,  
1026 Gregory Gibbs, Keri Greenfield, Adolfo Henriquez, Mahesh Joshi, Elaine Le, Nicole Mendez,  
1027 Claudia Moore, Aimee Ortiz, Mary Lou Riccio, Amie Rosenfeld, Ciny Singh, Monica  
1028 Sonnenberg, Rebecca Smither, Marcia Walker, and Willman Zambrano. Dr. Besser is supported  
1029 by NIH/NIA K01 AG063895, NIH/NIA R21 AG075291, and Alzheimer's Association Research  
1030 Grant (AARG-21-850963).

1031

1032 **Competing interests:**

1033 All authors have completed the ICMJE uniform disclosure form  
1034 at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: that the submitted work is supported by NIH  
1035 *R01AG071514, R01AG071514S1, R01NS101483, R01NS101483S1, RF1AG075901, and*  
1036 *R56AG074889*; there are no financial relationships with any organizations that might have an  
1037 interest in the submitted work in the previous three years; and no other relationships or activities  
1038 that could appear to have influenced the submitted work.

1039 **References**

- 1040 1. World Health Organization. Dementia n.d. [Available from: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/dementia)  
1041 [room/fact-sheets/detail/dementia](https://www.who.int/news-room/fact-sheets/detail/dementia).]
- 1042 2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al.  
1043 The diagnosis of dementia due to Alzheimer's disease: recommendations from the National  
1044 Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's  
1045 disease. *Alzheimers Dement*. 2011;7(3):263-9.
- 1046 3. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al.  
1047 Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB  
1048 Consortium. *Neurology*. 2017;89(1):88-100.
- 1049 4. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in  
1050 Early Alzheimer's Disease. *N Engl J Med*. 2023;388(1):9-21.
- 1051 5. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al.  
1052 Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis*. 2023;10(3):362-77.
- 1053 6. 2023 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2023;19(4):1598-695.
- 1054 7. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia  
1055 prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*.  
1056 2020;396(10248):413-46.
- 1057 8. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al.  
1058 Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-734.
- 1059 9. Montine TJ, Cholerton BA, Corrada MM, Edland SD, Flanagan ME, Hemmy LS, et al.  
1060 Concepts for brain aging: resistance, resilience, reserve, and compensation. *Alzheimers Res*  
1061 *Ther*. 2019;11(1):22.
- 1062 10. Wang Y, Pan Y, Li H. What is brain health and why is it important? *BMJ*.  
1063 2020;371:m3683.

- 1064 11. Irwin K, Sexton C, Daniel T, Lawlor B, Naci L. Healthy Aging and Dementia: Two Roads  
1065 Diverging in Midlife? *Front Aging Neurosci.* 2018;10:275.
- 1066 12. Chimthanawala NMA, Haria A, Sathaye S. Non-invasive Biomarkers for Early Detection  
1067 of Alzheimer's Disease: a New-Age Perspective. *Mol Neurobiol.* 2023. doi: 10.1007/s12035-  
1068 023-03578-3.
- 1069 13. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA  
1070 Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers*  
1071 *Dement.* 2018;14(4):535-62.
- 1072 14. Jack CR, Jr., Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al.  
1073 Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory  
1074 Decline Among Individuals Without Dementia. *JAMA.* 2019;321(23):2316-25.
- 1075 15. Tan CH, Bonham LW, Fan CC, Mormino EC, Sugrue LP, Broce IJ, et al. Polygenic  
1076 hazard score, amyloid deposition and Alzheimer's neurodegeneration. *Brain.* 2019;142(2):460-  
1077 70.
- 1078 16. Kikukawa T, Abe T, Ataka S, Saito H, Hasegawa I, Mino T, et al. Amyloid deposition and  
1079 CBF patterns predict conversion of mild cognitive impairment to dementia. *Neurol Sci.*  
1080 2018;39(9):1597-602.
- 1081 17. Rentz DM, Mormino EC, Papp KV, Betensky RA, Sperling RA, Johnson KA. Cognitive  
1082 resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau  
1083 Burden on cognitive performance. *Brain Imaging Behav.* 2017;11(2):383-90.
- 1084 18. Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181  
1085 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-  
1086 positron emission tomography. *Alzheimers Dement.* 2018;14(8):989-97.
- 1087 19. Reas ET, Hagler DJ, Jr., White NS, Kuperman JM, Bartsch H, Wierenga CE, et al.  
1088 Microstructural brain changes track cognitive decline in mild cognitive impairment. *Neuroimage*  
1089 *Clin.* 2018;20:883-91.

- 1090 20. Shim G, Choi KY, Kim D, Suh SI, Lee S, Jeong HG, et al. Predicting neurocognitive  
1091 function with hippocampal volumes and DTI metrics in patients with Alzheimer's dementia and  
1092 mild cognitive impairment. *Brain Behav.* 2017;7(9):e00766.
- 1093 21. Vasta R, Augimeri A, Cerasa A, Nigro S, Gramigna V, Nonnis M, et al. Hippocampal  
1094 Subfield Atrophies in Converted and Not-Converted Mild Cognitive Impairments Patients by a  
1095 Markov Random Fields Algorithm. *Curr Alzheimer Res.* 2016;13(5):566-74.
- 1096 22. Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, et al. ATN  
1097 profiles among cognitively normal individuals and longitudinal cognitive outcomes. *Neurology.*  
1098 2019;92(14):e1567-e79.
- 1099 23. Vos SJB, Duara R. The prognostic value of ATN Alzheimer biomarker profiles in  
1100 cognitively normal individuals. *Neurology.* 2019;92(14):643-4.
- 1101 24. Cummings J. The National Institute on Aging-Alzheimer's Association Framework on  
1102 Alzheimer's disease: Application to clinical trials. *Alzheimers Dement.* 2019;15(1):172-8.
- 1103 25. Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P. Impact of the biological  
1104 definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about  
1105 the role of vascular changes, inflammation, Lewy body pathology? *Transl Neurodegener.*  
1106 2018;7:12.
- 1107 26. Babulal GM, Quiroz YT, Albeni BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, et al.  
1108 Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias:  
1109 Update and areas of immediate need. *Alzheimers Dement.* 2019;15(2):292-312.
- 1110 27. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education  
1111 and occupation on the incidence of Alzheimer's disease. *JAMA.* 1994;271(13):1004-10.
- 1112 28. Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers.  
1113 *Alzheimers Res Ther.* 2014;6(2):21.
- 1114 29. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: the  
1115 caregiver experience of clinical care. *Parkinsonism Relat Disord.* 2010;16(6):388-92.

- 1116 30. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia:  
1117 caregiver burden and unmet needs. *Alzheimer Dis Assoc Disord.* 2010;24(2):177-81.
- 1118 31. Besser LM, Galvin JE. Perceived burden among caregivers of patients with  
1119 frontotemporal degeneration in the United States. *Int Psychogeriatr.* 2018:1-11.
- 1120 32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.  
1121 *Neurology.* 1993;43(11):2412-4.
- 1122 33. Stanley MPH, Hall KE, Mullally WJ. The Neurologic Exam. *Am J Med.* 2023;136(7):638-  
1123 44.
- 1124 34. Palmer JL, Coats MA, Roe CM, Hanko SM, Xiong C, Morris JC. Unified Parkinson's  
1125 Disease Rating Scale-Motor Exam: inter-rater reliability of advanced practice nurse and  
1126 neurologist assessments. *J Adv Nurs.* 2010;66(6):1382-7.
- 1127 35. S. Fahn RLE. Unified Parkinson's Disease Rating Scale. *Recent Developments in*  
1128 *Parkinson's Disease.* 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153-63,  
1129 293-304.
- 1130 36. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology.*  
1131 1967;17(5):427-42.
- 1132 37. Galvin JE. Improving the Clinical Detection of Lewy Body Dementia with the Lewy Body  
1133 Composite Risk Score. *Alzheimers Dement (Amst).* 2015;1(3):316-24.
- 1134 38. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al. Cerebral  
1135 blood flow in dementia. *Arch Neurol.* 1975;32(9):632-7.
- 1136 39. Tolea MI, Heo J, Chrisphonte S, Galvin JE. A Modified CAIDE Risk Score as a  
1137 Screening Tool for Cognitive Impairment in Older Adults. *J Alzheimers Dis.* 2021;82(4):1755-68.
- 1138 40. Dunietz GL, Chervin RD, Burke JF, Conceicao AS, Braley TJ. Obstructive sleep apnea  
1139 treatment and dementia risk in older adults. *Sleep.* 2021;44(9).
- 1140 41. Marinelli JP, Lohse CM, Fussell WL, Petersen RC, Reed NS, Machulda MM, et al.  
1141 Association between hearing loss and development of dementia using formal behavioural

- 1142 audiometric testing within the Mayo Clinic Study of Aging (MCSA): a prospective population-  
1143 based study. *Lancet Healthy Longev.* 2022;3(12):e817-e24.
- 1144 42. Li QY, Li XM, Hu HY, Ma YH, Ou YN, Wang AY, et al. Associations of Lung Function  
1145 Decline with Risks of Cognitive Impairment and Dementia: A Meta-Analysis and Systematic  
1146 Review. *J Alzheimers Dis.* 2023;92(3):853-73.
- 1147 43. Espeland MA, Newman AB, Sink K, Gill TM, King AC, Miller ME, et al. Associations  
1148 Between Ankle-Brachial Index and Cognitive Function: Results From the Lifestyle Interventions  
1149 and Independence for Elders Trial. *J Am Med Dir Assoc.* 2015;16(8):682-9.
- 1150 44. Flanigan PM, Khosravi MA, Leverenz JB, Tousi B. Color Vision Impairment  
1151 Differentiates Alzheimer Dementia From Dementia With Lewy Bodies. *J Geriatr Psychiatry*  
1152 *Neurol.* 2018;31(2):97-102.
- 1153 45. Colblindor. Color Arrangement Test 2021 [Available from: [https://www.color-](https://www.color-blindness.com/color-arrangement-test/)  
1154 [blindness.com/color-arrangement-test/](https://www.color-blindness.com/color-arrangement-test/)].
- 1155 46. Berg L. Clinical dementia rating. *The British Journal of Psychiatry.* 1984;145(3):339-.
- 1156 47. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for  
1157 assessment of primary degenerative dementia. *Am J Psychiatry.* 1982;139(9):1136-9.
- 1158 48. Benedict RH, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test–  
1159 Revised: Normative data and analysis of inter-form and test-retest reliability. *The Clinical*  
1160 *Neuropsychologist.* 1998;12(1):43-55.
- 1161 49. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al.  
1162 The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.  
1163 *J Am Geriatr Soc.* 2005;53(4):695-9.
- 1164 50. Reisberg D, Rappaport I, O'Shaughnessy M. Limits of working memory: The digit digit-  
1165 span. *Journal of Experimental Psychology: Learning, Memory, and Cognition.* 1984;10(2):203.

- 1166 51. Galvin JE, Chrisphonte S, Cohen I, Greenfield KK, Kleiman MJ, Moore C, et al.  
1167 Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the  
1168 Lewy body dementia module (LBD-MOD). *Alzheimer's & dementia*. 2021;17(10):1675-86.
- 1169 52. Butters N, Granholm E, Salmon DP, Grant I, Wolfe J. Episodic and semantic memory: A  
1170 comparison of amnesic and demented patients. *Journal of clinical and experimental*  
1171 *neuropsychology*. 1987;9(5):479-97.
- 1172 53. Ivanova I, Salmon DP, Gollan TH. The multilingual naming test in Alzheimer's disease:  
1173 clues to the origin of naming impairments. *Journal of the International neuropsychological*  
1174 *Society*. 2013;19(3):272-83.
- 1175 54. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage.  
1176 *Perceptual and motor skills*. 1958;8(3):271-6.
- 1177 55. Galvin JE, Tolea MI, Moore C, Chrisphonte S. The Number Symbol Coding Task: A brief  
1178 measure of executive function to detect dementia and cognitive impairment. *PLoS One*.  
1179 2020;15(11):e0242233.
- 1180 56. Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant  
1181 interview in dementia. *Neurology*. 2006;67(11):1942-8.
- 1182 57. Agrell B, Dehlin O. The clock-drawing test. 1998. *Age Ageing*. 2012;41 Suppl 3:iii41-5.
- 1183 58. Wechsler D. Wechsler memory scale-revised. Psychological Corporation. 1987.
- 1184 59. Rahman-Filipiak A, Sadaghiyani S, Davis K, Bhaumik AK, Paulson HL, Giordani B, et al.  
1185 Validation of the National Alzheimer's Coordinating Center (NACC) Lewy Body Disease Module  
1186 neuropsychological tests. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease*  
1187 *Monitoring*. 2022;14(1):e12279.
- 1188 60. Cahn-Hidalgo D, Benabou R, Kewin S. Validity, Reliability, and Psychometric properties  
1189 of Cognivue®, a quantitative assessment of cognitive impairment. *The American Journal of*  
1190 *Geriatric Psychiatry*. 2019;27(3):S212.

- 1191 61. Zigmond A, Snaith R, Kitamura T. The hospital anxiety and depression scale (HADS).  
1192 Acta psychiatr scand. 1983;67(6):361-70.
- 1193 62. Miller DK, Malmstrom TK, Andresen EM, Miller JP, Herning MM, Schootman M, et al.  
1194 Development and validation of a short portable sarcopenia measure in the African American  
1195 health project. J Gerontol A Biol Sci Med Sci. 2009;64(3):388-94.
- 1196 63. Wilkins CH, Roe CM, Morris JC. A brief clinical tool to assess physical function: the mini-  
1197 physical performance test. Arch Gerontol Geriatr. 2010;50(1):96-100.
- 1198 64. Dite W, Temple VA. A clinical test of stepping and change of direction to identify multiple  
1199 falling older adults. Arch Phys Med Rehabil. 2002;83(11):1566-71.
- 1200 65. Campbell CM RJ, Ciol MA, Shumway-Cook A. The effect of cognitive demand on timed  
1201 up and go performance in older adults with and without Parkinson disease. Journal of  
1202 Neurologic Physical Therapy. 2003;27(1):2-7.
- 1203 66. Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in  
1204 community-dwelling older adults using the Timed Up & Go Test. Phys Ther. 2000;80(9):896-  
1205 903.
- 1206 67. Clark RA, Pua YH, Fortin K, Ritchie C, Webster KE, Denehy L, et al. Validity of the  
1207 Microsoft Kinect for assessment of postural control. Gait Posture. 2012;36(3):372-7.
- 1208 68. Yeung LF, Cheng KC, Fong CH, Lee WC, Tong KY. Evaluation of the Microsoft Kinect  
1209 as a clinical assessment tool of body sway. Gait Posture. 2014;40(4):532-8.
- 1210 69. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A  
1211 Biol Sci Med Sci. 2007;62(7):722-7.
- 1212 70. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in  
1213 older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.
- 1214 71. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global  
1215 clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-95.

- 1216 72. Noah AM, Almghairbi D, Moppett IK. Optical coherence tomography in mild cognitive  
1217 impairment - Systematic review and meta-analysis. *Clin Neurol Neurosurg.* 2020;196:106036.
- 1218 73. Ashraf G, McGuinness M, Khan MA, Obtinalla C, Hadoux X, van Wijngaarden P. Retinal  
1219 imaging biomarkers of Alzheimer's disease: A systematic review and meta-analysis of studies  
1220 using brain amyloid beta status for case definition. *Alzheimers Dement (Amst).*  
1221 2023;15(2):e12421.
- 1222 74. Galvin JE, Kleiman MJ, Walker M. Using Optical Coherence Tomography to Screen for  
1223 Cognitive Impairment and Dementia. *J Alzheimers Dis.* 2021;84(2):723-36.
- 1224 75. Camargo M, Pais MV, Bellan AFR, Tahira AC, Dos Santos B, Sant'Ana L, et al. Impact  
1225 of Cognitive Demand on Eye Movement Pattern in Patients with Alzheimer's Disease. *J*  
1226 *Alzheimers Dis.* 2022;90(1):85-95.
- 1227 76. Tao L, Wang Q, Liu D, Wang J, Zhu Z, Feng L. Eye tracking metrics to screen and  
1228 assess cognitive impairment in patients with neurological disorders. *Neurol Sci.*  
1229 2020;41(7):1697-704.
- 1230 77. Mosimann UP, Muri RM, Burn DJ, Felblinger J, O'Brien JT, McKeith IG. Saccadic eye  
1231 movement changes in Parkinson's disease dementia and dementia with Lewy bodies. *Brain.*  
1232 2005;128(Pt 6):1267-76.
- 1233 78. Mueller KD, Hermann B, Mecollari J, Turkstra LS. Connected speech and language in  
1234 mild cognitive impairment and Alzheimer's disease: A review of picture description tasks. *J Clin*  
1235 *Exp Neuropsychol.* 2018;40(9):917-39.
- 1236 79. Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, et al. High  
1237 amyloid burden is associated with fewer specific words during spontaneous speech in  
1238 individuals with subjective cognitive decline. *Neuropsychologia.* 2019;131:184-92.
- 1239 80. Mueller KD, Van Hulle CA, Kosciak RL, Jonaitis E, Peters CC, Betthausen TJ, et al.  
1240 Amyloid beta associations with connected speech in cognitively unimpaired adults. *Alzheimers*  
1241 *Dement (Amst).* 2021;13(1):e12203.

- 1242 81. Lagun D, Manzanares C, Zola SM, Buffalo EA, Agichtein E. Detecting cognitive  
1243 impairment by eye movement analysis using automatic classification algorithms. *J Neurosci*  
1244 *Methods*. 2011;201(1):196-203.
- 1245 82. Gills JL, Bott NT, Madero EN, Glenn JM, Gray M. A short digital eye-tracking  
1246 assessment predicts cognitive status among adults. *GeroScience*. 2021;43(1):297-308.
- 1247 83. Alzheimer's Disease Neuroimaging Initiative. ADNI 3 2017 [Available from:  
1248 <https://adni.loni.usc.edu/adni-3/>.
- 1249 84. Kleiman MJ, Chang LC, Galvin JE. The Brain Health Platform: Combining Resilience,  
1250 Vulnerability, and Performance to Assess Brain Health and Risk of Alzheimer's Disease and  
1251 Related Disorders. *J Alzheimers Dis*. 2022;90(4):1817-30.
- 1252 85. Galvin JE, Kleiman MJ, Chrisphonte S, Cohen I, Disla S, Galvin CB, et al. The  
1253 Resilience Index: A Quantifiable Measure of Brain Health and Risk of Cognitive Impairment and  
1254 Dementia. *J Alzheimers Dis*. 2021;84(4):1729-46.
- 1255 86. Kleiman MJ, Galvin JE. The Vulnerability Index: A weighted measure of dementia and  
1256 cognitive impairment risk. *Alzheimers Dement (Amst)*. 2021;13(1):e12249.
- 1257 87. Wilcock D, Jicha G, Blacker D, Albert MS, D'Orazio LM, Elahi FM, et al. MarkVCID  
1258 cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. *Alzheimers Dement*.  
1259 2021;17(4):704-15.
- 1260 88. Lu H, Kashani AH, Arfanakis K, Caprihan A, DeCarli C, Gold BT, et al. MarkVCID  
1261 cerebral small vessel consortium: II. Neuroimaging protocols. *Alzheimers Dement*.  
1262 2021;17(4):716-25.
- 1263 89. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature  
1264 and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update.  
1265 *Acta Neuropathol*. 2010;119(1):1-4.

- 1266 90. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al.  
1267 Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.  
1268 *Brain*. 2011;134(Pt 9):2456-77.
- 1269 91. Galvin JE. Prevention of Alzheimer's Disease: Lessons Learned and Applied. *J Am*  
1270 *Geriatr Soc*. 2017;65(10):2128-33.
- 1271 92. Galvin JE. Advancing personalized treatment of Alzheimer's disease: a call for the N-of-1  
1272 trial design. *Futur Neurol*. 2018;13(3):151-60.
- 1273 93. Academy of Medical Sciences. Stratified, personalised or P4 medicine: a new direction  
1274 for placing the patient at the centre of healthcare and health education. 2015.
- 1275 94. Li QY, Tang BH, Wu YE, Yao BF, Zhang W, Zheng Y, et al. Machine Learning: a New  
1276 Approach for Dose Individualization. *Clin Pharmacol Ther*. 2023. doi: 10.1002/cpt.3049.
- 1277 95. Devi G. A how-to guide for a precision medicine approach to the diagnosis and  
1278 treatment of Alzheimer's disease. *Front Aging Neurosci*. 2023;15:1213968.
- 1279 96. Adewale BA, Coker MM, Ogunniyi A, Kalaria RN, Akinyemi RO. Biomarkers and Risk  
1280 Assessment of Alzheimer's Disease in Low- and Middle-Income Countries. *J Alzheimers Dis*.  
1281 2023. doi: 10.3233/JAD-221030.
- 1282 97. Kleiman MJ, Ariko T, Galvin JE, Alzheimer's Disease Neuroimaging I. Hierarchical Two-  
1283 Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer's  
1284 Disease and Related Dementias. *J Alzheimers Dis*. 2023;91(2):895-909.
- 1285 98. Kleiman MJ, Barenholtz E, Galvin JE, Alzheimer's Disease Neuroimaging I. Screening  
1286 for Early-Stage Alzheimer's Disease Using Optimized Feature Sets and Machine Learning. *J*  
1287 *Alzheimers Dis*. 2021;81(1):355-66.
- 1288 99. Centers for Disease Control and Prevention. Exposome and Exposomics 2022  
1289 [Available from: <https://www.cdc.gov/niosh/topics/exposome/default.html>].

- 1290 100. University of Wisconsin School of Medicine and Public Health. 2015 Area Deprivation  
1291 Index v2.0 [Available from: <https://www.neighborhoodatlas.medicine.wisc.edu/>].
- 1292 101. U.S. Department of the Interior. U.S. Geological Survey Landsat Missions [Available  
1293 from: <https://landsat.usgs.gov/>].
- 1294 102. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. *Science*.  
1295 2001;293(5532):1068-70.
- 1296 103. Li S, Hursting SD, Davis BJ, McLACHLAN JA, Barrett JC. Environmental exposure, DNA  
1297 methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. *Annals of*  
1298 *the New York Academy of Sciences*. 2003;983(1):161-9.
- 1299 104. Robertson KD. DNA methylation and human disease. *Nature Reviews Genetics*.  
1300 2005;6(8):597-610.
- 1301 105. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of  
1302 ageing. *Nat Rev Genet*. 2018;19(6):371-84.
- 1303 106. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol*.  
1304 2013;14(10):R115.
- 1305 107. McCrory C, Fiorito G, Hernandez B, Polidoro S, O'Halloran AM, Hever A, et al.  
1306 Association of 4 epigenetic clocks with measures of functional health, cognition, and all-cause  
1307 mortality in The Irish Longitudinal Study on Ageing (TILDA). *bioRxiv*. 2020.  
1308 doi: <https://doi.org/10.1101/2020.04.27.063164>
- 1309 108. Bell CG, Xia Y, Yuan W, Gao F, Ward K, Roos L, et al. Novel regional age-associated  
1310 DNA methylation changes within human common disease-associated loci. *Genome Biol*.  
1311 2016;17(1):193.
- 1312 109. Zheng Y, Habes M, Gonzales M, Pomponio R, Nasrallah I, Khan S, et al. Mid-life  
1313 epigenetic age, neuroimaging brain age, and cognitive function: coronary artery risk  
1314 development in young adults (CARDIA) study. *Aging (Albany NY)*. 2022;14(4):1691-712.

- 1315 110. Nilsson E, Jansson PA, Perfilyev A, Volkov P, Pedersen M, Svensson MK, et al. Altered  
1316 DNA methylation and differential expression of genes influencing metabolism and inflammation  
1317 in adipose tissue from subjects with type 2 diabetes. *Diabetes*. 2014;63(9):2962-76.
- 1318 111. Benton MC, Johnstone A, Eccles D, Harmon B, Hayes MT, Lea RA, et al. An analysis of  
1319 DNA methylation in human adipose tissue reveals differential modification of obesity genes  
1320 before and after gastric bypass and weight loss. *Genome biology*. 2015;16:1-21.
- 1321 112. Johnson ND, Conneely KN. The role of DNA methylation and hydroxymethylation in  
1322 immunosenescence. *Ageing Res Rev*. 2019;51:11-23.
- 1323 113. Galvin JE. The Quick Dementia Rating System (Qdrs): A Rapid Dementia Staging Tool.  
1324 *Alzheimers Dement (Amst)*. 2015;1(2):249-59.
- 1325 114. Defranceso M, Schocke M, Messner HJ, Deisenhammer EA, Hinterhuber H, Marksteiner  
1326 J, et al. [Conversion from MCI (Mild Cognitive Impairment) to Alzheimer's disease: diagnostic  
1327 options and predictors]. *Neuropsychiatr*. 2010;24(2):88-98.
- 1328 115. Lacey RJ, Jordan KP, Croft PR. Does attrition during follow-up of a population cohort  
1329 study inevitably lead to biased estimates of health status? *PLoS One*. 2013;8(12):e83948.
- 1330 116. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and  
1331 Powerful Approach to Multiple Testing. *J R Stat Soc B*. 1995;57(1):289-300.
- 1332 117. Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ. Shared random effects  
1333 analysis of multi-state Markov models: application to a longitudinal study of transitions to  
1334 dementia. *Stat Med*. 2007;26(3):568-80.
- 1335 118. Jackson CH. Multi-state models for panel data: the msm package for R. *J Stat Softw*.  
1336 2011;38(8):1-29.
- 1337 119. Hollingshead AA. Four-factor index of social status. Yale Univesrity, New Haven, CT  
1338 1975.

- 1339 120. Li MJ, Black DS, Garland EL. The Applied Mindfulness Process Scale (AMPS): A  
1340 process measure for evaluating mindfulness-based interventions. *Pers Individ Dif.* 2016;93:6-  
1341 15.
- 1342 121. Liu X, Morris MC, Dhana K, Ventrelle J, Johnson K, Bishop L, et al. Mediterranean-  
1343 DASH Intervention for Neurodegenerative Delay (MIND) study: Rationale, design and baseline  
1344 characteristics of a randomized control trial of the MIND diet on cognitive decline. *Contemp Clin*  
1345 *Trials.* 2021;102:106270.
- 1346 122. Galvin JE, Tolea MI, Rosenfeld A, Chrisphonte S. The Quick Physical Activity Rating  
1347 (QPAR) scale: A brief assessment of physical activity in older adults with and without cognitive  
1348 impairment. *PLoS One.* 2020;15(10):e0241641.
- 1349 123. Galvin JE, Tolea MI, Chrisphonte S. The Cognitive & Leisure Activity Scale (CLAS): A  
1350 new measure to quantify cognitive activities in older adults with and without cognitive  
1351 impairment. *Alzheimers Dement (N Y).* 2021;7(1):e12134.
- 1352 124. Scheim AI, Bauer GR. The Intersectional Discrimination Index: Development and  
1353 validation of measures of self-reported enacted and anticipated discrimination for  
1354 intercategory analysis. *Soc Sci Med.* 2019;226:225-35.
- 1355 125. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health*  
1356 *Soc Behav.* 1983;24(4):385-96.
- 1357 126. Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional  
1358 activities in older adults in the community. *J Gerontol.* 1982;37(3):323-9.
- 1359 127. Boeve BF, Molano JR, Ferman TJ, Lin SC, Bieniek K, Tippmann-Peikert M, et al.  
1360 Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a  
1361 community-based sample. *J Clin Sleep Med.* 2013;9(5):475-80.
- 1362 128. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB  
1363 fluctuations: specific features that reliably differentiate DLB from AD and normal aging.  
1364 *Neurology.* 2004;62(2):181-7.

- 1365 129. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The  
1366 Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.  
1367 Neurology. 1994;44(12):2308-14.  
1368  
1369

1370 **Table 1. Participant questionnaires**  
1371

<b>Instrument/form</b>	<b>Data collected, examples</b>
Demographics and basic information	Age, gender, race, ethnicity, primary language, years of education, major occupation, retired status, mobility aids, living situation, housing type, study partner relation, address, other state of residence if snowbird (in Florida for winter only)
Hollingshead Index of Social Position (119)	Occupation and education level categories
Participant's family history	Family history of ADRD, Parkinson's disease, stroke, heart disease, diabetes, depression
Advanced care planning	Living will, disability care insurance, etc.
Global health screening	Self-rated physical and mental health, etc.
Participant's medical history	Traumatic brain injury, falls, seizures, high cholesterol, thyroid disease, alcohol and substance use, etc.
Current prescribed and over-the-counter medication	Name, dosage, and frequency of medication
Allergies and diet	Medication allergies, food/environmental allergies, diet restrictions (e.g., gluten free, vegetarian)
Neighborhood questionnaire	Presence and use of parks and greenspaces, crime and safety, presence of sidewalks and grocery stores, trust in neighbors
Depression, Anxiety, and Apathy Assessment (DA <sup>3</sup> )	Rating how often over the past 2 weeks "I feel tense and unable to relax", "I sit by and let things happen around me", etc.
Symptom Ratings	Memory and recall, orientation, decision making and problem solving abilities, activities outside the home, function at home and hobby activities, toileting and personal hygiene, behavior and personality changes, language and communication abilities, mood, attention and concentration
Hospital Anxiety and Depression Scale (61)	"I feel tense", "I have worrying thoughts", "I feel slowed down", etc.
Applied Mindfulness Scale (120)	"When faced with a stressful event, I relax my body when I am tense", etc.
The Healthy Brain 9 (HB9)	Compared to 5 years ago, participants rate current ability in "taking care of financial matters, "carrying out my everyday activities", etc.
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet(121)	Over past 3 months, consumption of green leafy vegetables, berries, nuts, beans, etc.

Physical Activity Scale (QPAR) (122)	Days per week and hours per day in various activities such as sitting, walking outside, and light, moderate, and strenuous activities
Cognitive and Leisure Activities (CLAS) (123)	Frequency participating in activities such as socializing with friends, volunteering, exercise, etc.
Autonomic Symptoms Checklist (51)	Over past six months, presence and age of onset of various symptoms such as difficulty swallowing, weight loss, excessive sweating, etc.
Brain Health Over the Lifecourse	Residential addresses at age 10, 25, 40, 65; physical, cognitive, social activity, weight, and diet at ages 25, 40, and 65; lifelong perceived discrimination (124) (e.g., "A doctor, nurse, or other health care provider might treat me poorly"); coping over the lifecourse (125) (e.g., over lifetime, frequency that participant has felt unable to control important things in life).

---

1372

1373

1374

1375 **Table 2. Questionnaires completed by study partner**  
1376

<b>Instrument/form</b>	<b>Data collected, examples</b>
Demographics and basic information	Age, gender, race, ethnicity, primary language, years of education, major occupation, retired status, living situation, relationship to participant, participant's global income, financial costs of caregiving
Functional Activities Questionnaire (126)	Participants ability to carry out activities over past 4 weeks (e.g., keeping track of current events, preparing a balanced meal)
Symptom Rating (of the participant)	Memory and recall, orientation, decision making and problem solving abilities, activities outside the home, function at home and hobby activities, toileting and personal hygiene, behavior and personality changes, language and communication abilities, mood, attention and concentration
Sleep Evaluation (of the participant)	Rate participant problems with nighttime sleep and daytime sleepiness in past month, and presence of snoring or vivid dreams/nightmares
Mayo Sleep Questionnaire (127)	Rate participant sleep behaviors and quality (e.g., "have you ever seen the participant appear to act out his/her dreams while sleeping")
Mayo Fluctuation Questionnaire (128)	Assesses whether participant has symptoms of cognitive fluctuation (e.g., daytime drowsiness; unclear, disorganized flow of ideas) and frequency, duration, and situations in which it occurs.
Neuropsychiatric Inventory (129)	Rating for the participant on the presence and severity of symptoms (e.g., delusions, hallucinations, agitation/aggression)
Frontal Behavioral Battery	Rating for the participant on the presence and severity of symptoms (e.g., difficulty speaking, difficulty swallowing, hit or tried to hit someone, etc.)
VHDQ	Assess whether in the past 6 months, participant had visual or auditory hallucinations
Positive and Negative Appraisals of Caregiving	Ratings on various negative (e.g., "feel stress, strain, or anger when dealing with the participant") and positive feelings (e.g., "I am the best person to care for participant") toward caregiving.

1377

1378

1379 **Table 3. In-person clinician assessments and procedures**

<b>Assessment/Procedure</b>	<b>Visit done/assessed<sup>a</sup></b>
Blood draw	Baseline visit, every follow-up visit
Neuropsychological evaluation	Baseline visit, every follow-up visit
Clinical Dementia Rating (CDR®)(32)	Baseline visit, every follow-up visit
Physical Function assessment	Baseline visit, every follow-up visit
Color Blind Test (45)	Baseline visit, every follow-up visit
Physical exam	Baseline visit, every follow-up visit
Neurological exam	Baseline visit, every follow-up visit
Watch PAT / Sleep study	Baseline visit, every follow-up visit
Ankle Brachial Index (ABI)	Baseline visit, every follow-up visit
Pulmonary Function Test (PFT)	Baseline visit, every follow-up visit
Audiometry Hearing test	Baseline visit, every follow-up visit
Optical Coherence Tomography (OCT)	Baseline visit, every follow-up visit
Neurobehavioral markers	Baseline visit, every follow-up visit
Cognivue (60)	Baseline visit, every follow-up visit
Magnetic Resonance Imaging (MRI)	Baseline, every two years afterward
Positron Emission Tomography (PET)	Baseline visit (optional)

<sup>a</sup> IRB-approved modifications to the HBI protocol may add or delete additional assessments/procedures and/or their frequency

1380

1381